<SEC-DOCUMENT>0001193125-14-124011.txt : 20140331
<SEC-HEADER>0001193125-14-124011.hdr.sgml : 20140331
<ACCEPTANCE-DATETIME>20140331164034
ACCESSION NUMBER:		0001193125-14-124011
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140331
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140331
DATE AS OF CHANGE:		20140331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		14730620

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d701442d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): March&nbsp;31, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Corporation plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-21392</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street 28-32, Dublin 2,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ireland</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Former
name or former address, if changed since last report </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;1.01. Entry into a Material Definitive Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;31, 2014, Amarin Pharmaceuticals Ireland Limited (&#147;<U>APIL</U>&#148;) and Amarin Pharma, Inc. (&#147;<U>API</U>&#148;, and together with
APIL, &#147;<U>Amarin</U>&#148;), each a wholly-owned subsidiary of Amarin Corporation plc (the &#147;<U>Company</U>&#148;), entered into a Co-Promotion Agreement (the &#147;<U>Agreement</U>&#148;) with Kowa Pharmaceuticals America, Inc. related to
the commercialization of Vascepa&reg; (icosapent ethyl) capsules in the United States. Under the terms of the Agreement, Amarin granted to Kowa Pharmaceuticals America the right to be the sole co-promoter, together with API, of Vascepa in the United
States during the term. The initial term of the Agreement extends through 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the term, Kowa Pharmaceuticals America and Amarin have agreed to
use commercially reasonable efforts to promote, detail and optimize sales of Vascepa in the United States and have agreed to specific performance requirements detailed in the Agreement. The performance requirements include a negotiated minimum
number of details to be delivered by each party in the first and second position, and the use of a negotiated number of minimum sales representatives from each party, including no less than 250 Kowa Pharmaceuticals America sales representatives.
Kowa Pharmaceuticals America has also agreed to continue to bear the costs incurred for its sales force associated with the commercialization of Vascepa and to pay for certain incremental costs resulting from the Agreement associated with the use of
its sales force, such as sample costs and costs for promotional and marketing materials. Amarin remains responsible for marketing efforts related to Vascepa, and providing to Kowa Pharmaceuticals America all promotional materials and samples,
subject to such cost sharing arrangement. Additionally, Amarin has agreed to use commercially reasonable efforts to maintain a minimum amount of inventory of Vascepa for use in the United States. Amarin&#146;s commitments under the Agreement are
within its commercialization plans prior to the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kowa Pharmaceuticals America has agreed to limitations on its ability to undertake specified
commercialization-related activities on certain products that may be competitive with Vascepa in the United States during the term and for specified periods thereafter. There are no restrictions on Kowa Pharmaceuticals America&#146;s ability to
commercialize LIVALO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pitavastatin), but Kowa Pharmaceuticals America has agreed to certain guidelines related to the promotion of its product LIPOFEN<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (fenofibrate capsules, USP) that substantially limit current promotional efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin and Kowa
Pharmaceuticals America agreed to form a joint steering committee to oversee the day-to-day promotion, detailing and compliance activities of the parties associated with the Agreement. Kowa Pharmaceuticals America will have the opportunity through
the joint steering committee to confer with or make recommendations to Amarin regarding such activities. However, Amarin has final decision-making authority and responsibility for all sales, marketing and promotional activities related to Vascepa.
Amarin retains the exclusive right to make, sell and offer Vascepa for sale and is responsible for matters relating to the regulatory status of Vascepa and to pharmacovigilance. The Agreement also contains indemnification, record keeping, audit
rights, reporting obligations, and representations and warranties that are customary for an arrangement of this type. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin will continue to recognize
all revenue from sales of Vascepa under the Agreement. In exchange for Kowa Pharmaceuticals America&#146;s co-promotional services, Kowa Pharmaceuticals America is entitled to a quarterly co-promotion fee based on a percentage of Vascepa gross
margins that increases during the Agreement&#146;s term, from the high single digits in 2014 to the low twenty percent levels in 2018. The co-promotion fee also varies based on sales levels and whether the U.S. Food and Drug Administration
(&#147;FDA&#148;) has approved an ANCHOR indication labeling expansion for Vascepa or has permitted the use of data generated to support obtaining FDA approval of the ANCHOR indication in the promotion of Vascepa, in which case the co-promotion fee
would be decreased if specified requirements are met. In certain circumstances, upon the earlier of the expiration or termination of the Agreement in accordance with its terms, Kowa Pharmaceuticals America may be eligible for a co-promotion tail fee
equal to declining fractions of the co-promote fee in effect prior to such expiration or termination for periods ranging from one to three years following such expiration or termination. For example, in the event of a change of control of Amarin,
Amarin may terminate the Agreement, which would result in the payment of a residual tail fee to Kowa Pharmaceuticals America calculated as provided above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the initial term, provided that gross sales for Vascepa in the United States in 2018 exceed a negotiated dollar threshold as set forth in the Agreement,
the Agreement may be extended by mutual agreement of Amarin and Kowa Pharmaceuticals America for an additional two years. Each party may terminate the Agreement before the expiration of the initial term upon the uncured material breach of the other
party, upon the bankruptcy or insolvency of the other party, after a force majeure that persists for 90 days, and upon certain criminal proceedings against the other party or certain of its constituents. In addition, each party may terminate the
Agreement upon a change of control of either party, upon the failure of the other party to meet certain minimum detail requirements, or in the event that gross sales of Vascepa in the United States do not exceed minimum thresholds, which thresholds
increase each year during the term of the Agreement. Amarin may terminate the Agreement upon Kowa Pharmaceuticals America&#146;s promotion of any other product that, despite its approved label, is being used to reduce triglyceride levels in 50% or
more of its prescribed applications. Other termination provisions apply. Certain restrictions on Kowa Pharmaceuticals America&#146;s promotion of specified competitive products to Vascepa apply after termination of the Agreement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the terms of the Agreement is qualified in its entirety by reference to the
available text of the Agreement, a redacted copy of which will be filed as an exhibit to the Company&#146;s Quarterly Report on Form 10-Q for the three months ending March&nbsp;31, 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;31, 2014, the
Company issued a press release entitled &#147;Amarin and Kowa Pharmaceuticals America Announce U.S. Co-Promotion Agreement for Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) Capsules&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The contents of the press
release are deemed to be filed for purposes of the Securities Exchange Act of 1934, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* * * </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated March&nbsp;31, 2014</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">March&nbsp;31, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Amarin Corporation plc</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Thero</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">John Thero</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit&nbsp;Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated March&nbsp;31, 2014</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d701442dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g701442ex99_1pg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amarin and Kowa Pharmaceuticals America, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Announce U.S. Co-Promotion Agreement for Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) Capsules
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151;Agreement to More than Double Vascepa Sales Calls and </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Expand Promotional Breadth and Depth &#151; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEDMINSTER, N.J., DUBLIN, Ireland, and MONTGOMERY, AL, March&nbsp;31, 2014 &#151; Amarin Corporation plc&nbsp;(Nasdaq: AMRN) and Kowa Pharmaceuticals America,
Inc., two biopharmaceutical companies focused on the development and commercialization of therapeutics to improve cardiovascular health, today announced an agreement to co-promote Amarin&#146;s flagship product, Vascepa<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules, in the United States. Vascepa is approved for use in the United States as an adjunct to diet to reduce triglyceride levels in adult patients with severe
(<U>&gt;</U>500 mg/dL) hypertriglyceridemia. In bringing together two companies focused on the primary care and cardiovascular health communities, the agreement is designed to benefit a greater number of patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement provides for the near-term expansion of Vascepa promotional efforts through use of Kowa Pharmaceuticals America&#146;s sales force to
substantially increase both the number of sales targets reached and the frequency of sales calls on existing sales targets. Under the agreement, Kowa Pharmaceuticals America will employ its sales force of approximately 250 sales representatives to
co-promote Vascepa in the United States augmenting Amarin&#146;s approximately 130 sales representatives and more than doubling Amarin&#146;s current sales detail frequency through primary and secondary details. Kowa Pharmaceuticals America&#146;s
sales force is expected to begin its Vascepa promotional efforts in May 2014 to its existing target audience of primary care physicians and cardiologists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kowa Pharmaceuticals America has a successful track record of launching and commercializing drugs for the treatment of cardiovascular disease in the United
States, including its flagship statin product, LIVALO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pitavastatin). Kowa Pharmaceuticals America&#146;s sales team calls on many of the same physicians who are current and potential
prescribers of Vascepa. The planned expansion in Vascepa promotional effort under the co-promotion agreement is expected to build on the significant base of progress Amarin has made and to help expand the use of Vascepa for patients in need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the agreement, Kowa Pharmaceuticals America will pay for certain incremental costs associated with the use of its sales force that are associated with
the commercialization of Vascepa, such as sample costs and costs for promotional and marketing materials. Each party has agreed to deliver specified minimal primary detail equivalents and spend specified minimal amounts on sample, promotional and
marketing costs. Amarin&#146;s commitments under the agreement are within its commercialization plans prior to the agreement. Amarin will continue to control marketing of the product and recognize all revenue from sales of Vascepa. Amarin will
compensate Kowa Pharmaceuticals America with a co-promotion fee based on a percentage of Vascepa gross margins that increase during the agreement&#146;s term, from the high single digits in 2014 to the low twenty percent levels in 2018, subject to
certain adjustments. The initial term of the agreement extends through 2018. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;With the support of Kowa Pharmaceuticals America, we anticipate increasing the rate of Vascepa prescription
and revenue growth as together we help educate physicians regarding the use of Vascepa as therapy for severe hypertriglyceridemia through promotion of its highly favorable efficacy and safety profile,&#148; stated John F. Thero, President and Chief
Executive Officer of Amarin. &#147;Kowa&#146;s commercial reach and customer base make it a valuable commercial partner for Amarin. Kowa Pharmaceuticals America has a highly motivated and talented sales force that complements Amarin&#146;s sales
team and substantially increases its reach into our target market. Kowa Pharmaceuticals America has a strong and proven leadership team, a solidified presence in the cardiovascular and lipid-lowering marketplace and a track record of success. We
look forward to a successful collaboration with Kowa Pharmaceuticals America and to creating significant value for both companies and their customers.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Our goal has been to help physicians address patient-care concerns by offering important medications and support programs,&#148; said Ben Stakely, Chief
Executive Officer and President of Kowa Pharmaceuticals America, Inc. &#147;We have been very impressed with Vascepa&#146;s favorable efficacy and safety profile and look forward to working with Amarin to significantly expand Vascepa promotional
efforts in the United States. By entering into this agreement with Amarin, we can now speak to a range of important lipid-related issues that impact our target physicians&#146; practices. We are proud of our current portfolio and excited about
bringing new FDA-approved treatments, such as Vascepa, to more patients in need. With its favorable efficacy and safety profile, our team is excited about this opportunity to work with Amarin to help maximize the value of Vascepa.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vascepa commercialization progress </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa was launched
by Amarin in early 2013. Sales of Vascepa in 2013 resulted in net revenues for Amarin of approximately $26.4 million. Vascepa labeling reflects a spectrum of favorable effects on lipid and lipoprotein parameters at 4 g/day, including statistically
significant reductions in TG, Apo B, VLDL-C, and non-HDL-C, with no increase in LDL-C, also known as bad cholesterol, and a safety profile that is comparable to placebo. The most common reported adverse reaction (incidence &gt; 2% and greater than
placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). With the benefit of this clinical profile, Amarin made significant progress throughout 2013 in multiple areas of the Vascepa commercialization plan. Vascepa is now available on formulary
to over 200&nbsp;million lives in the United States, including over 100&nbsp;million with Tier 2 coverage. The conversion of these lives to Tier 2 status has helped enable Amarin to grow the Vascepa prescriber base to over 16,000 physicians since
launch. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Vascepa&reg;&nbsp;(icosapent ethyl) capsules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(icosapent ethyl) capsules, known in scientific literature as AMR101, is a highly
pure-EPA&nbsp;omega-3 prescription product in a 1 gram capsule. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Indications and Usage </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information for Vascepa </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components and should be used with caution in patients with known hypersensitivity to fish and/or
shellfish. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most common reported adverse reaction (incidence &gt;2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT&nbsp;<U>WWW.VASCEPA.COM</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa has been approved for use by the FDA as an adjunct to diet to reduce triglyceride levels in adult patients with severe (<U>&gt;</U>500 mg/dL)
hypertriglyceridemia. Vascepa is under various stages of development for potential use in other indications that have not been approved by the FDA. Nothing in this press release should be construed as marketing the use of Vascepa in any indication
that has not been approved by the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.
Amarin&#146;s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl),
Amarin&#146;s first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kowa Company Ltd. and Kowa Pharmaceuticals America, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kowa Company, Ltd. (Kowa) is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various
manufacturing and trading activities in the fields of pharmaceutical, life science, information technology, textiles, machinery and various consumer products. Kowa&#146;s pharmaceutical division is focused on cardiovascular therapeutics, with sales
of the company&#146;s flagship product, LIVALO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pitavastatin) totaling &yen; 51 billion ($505 million*) in Japan fiscal year ending March 2013, and was launched in the United States in June
2010. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kowa Pharmaceuticals America, Inc. is a cardiovascular and primary care pharmaceutical company focused primarily in the area of cardiology. The
company started in 2001 as ProEthic Pharmaceuticals, Inc., and a majority stake in the company was acquired by Kowa Company, Ltd. in September 2008. A privately held company, Kowa Pharmaceuticals America focuses its efforts on the acquisition,
licensing and marketing of pharmaceutical products. For more information about Kowa Pharmaceuticals America, visit <U>www.kowapharma.com</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">exchange rate used 1USD = 102JPY<B> </B> </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements, including statements about the potential for increased prescription and revenue growth from the sale of
Vascepa in connection with the co-promotion agreement; the efficacy, safety and therapeutic benefits of Vascepa and the commercial success of Vascepa and the co-promotion effort and agreement. These forward-looking statements are not promises or
guarantees and involve substantial risks and uncertainties. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular, the ability to effectively commercialize Vascepa will depend in part on the ability to create
market demand for Vascepa through education, marketing and sales activities, to achieve market acceptance of Vascepa, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial
supply at a competitive price, and to maintain patent protection. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated with new collaborations
and the ability of commercial partners to work together effectively to achieve intended results; related cost may increasing beyond expectations; and the risk that patent applications may not result in issued patents. A further list and description
of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. Existing and
prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether
as a result of new information, future events or circumstances or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of other information about Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations
website (http://www.amarincorp.com/investor-splash.html), including but not limited to investor presentations and investor FAQs,&nbsp;Securities and Exchange Commission&nbsp;filings, press releases, public conference calls and webcasts. The
information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including
our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website
that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin contact information: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Farrell or Joseph
Bruno </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (908)&nbsp;719-1315
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investor.relations@amarincorp.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kowa
Pharmaceuticals America, Inc. contact information: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lisa Garman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kowa Pharmaceuticals America, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mobile: 334-296-1917 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lgarman@kowapharma.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g701442ex99_1pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g701442ex99_1pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`60)T`P$1``(1`0,1`?_$`/4``0`!!`(#`0``````
M```````*!P@)"P$&`@,$!0$!``$$`P$!``````````````<!!08(`@0)`PH0
M```&`0,"`P,%!@\(#0T```$"`P0%!@<`$0@2"2$Q$U$4"D%AD2(5<3)2(Q87
M\(&AL<'1<I(S-!@X6!DYX4*R<R35=Y=#LR4UM<6V)T>'*'@:\6*"1+1%)C9F
M-[=H*1$``0($`P0%!@@)!0T&!P$``0(#`!$$!2$2!C%!!PA187$B$X&1,A05
M":&QT4)RDB,6\,%28K(S<S47@J)3)#3A\<+20Y.STU0EE1@98T1T)C96XH.C
MA-15=4;_V@`,`P$``A$#$0`_`)_&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&
MD(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0
MAI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI".
M!\M(133)69,2X:A5+'EO)=%QK`IB8#2UXM,+66&Y"`<Q2N)=XU(<X%\>D-S#
MOY>(:Z=;<*"W-^-7OM,M=*U!(\Y,9;I'0.N-?W`6G0]HN5WN9_R5)3NU"\</
M1:2HRZY`1BSRYWZ>V_BQ1RRC<K3N6I=L8Y#1N**;,SZ"IB?>@VL4HE!5)R"A
MO`HIOS!X[ZC^X<7-$4$PW5*J7`9?8(4L>54LO9WHW-T-[M+FQUFA-15V6FL=
M`N4G+E5-,J'TF&R]4IE^<R.C$Q9.^[]G(+,3]2/X:]N?+N36*H`DRL=H^WWJ
MGO!C`0/>JY0:W.L4TBF$-Q^VPW$=O#6.+XL7JYJ*-,V2I>'S5N$@$=,FT+&/
MTAUQL+3>[0X7Z"IA4\?>*UCL]2G%3%/X*1EE/NOUK[*R?_M//'S$Y"_$;9F5
M)^1W&+$V$(UX43(NIF%KL0]8)E*`[NR9-R+,.!5'J#P^SMQ'R+X"&J>U^-%T
M`-+14M$/ST@GSK=_P8^IX6^ZBT"C_?VL+YJ&J;P4EIU]U*S^:;?0-)`EO\:7
M28\`XL?$6Y,/U6[F=C3&C9R8OK-HF1J\0HS(H<"*`@;'6)7"W4BF81#I<[CM
MX&WVT-@XQW#&INC%-]#(/T63L[8Y_P`9_=4:11_N/0%VN[R!W5.-U#H60,,W
MKUS`Q(QFW+&<H^,.R)W!K\47.8>Z?D-1\[3<&?M825RU:(\JXB(HE1/)7JGI
MKH'WW.`MD0)X@4H^>JIX::NJ@3<K\\I1VY2X?ASH'\T1]_\`J(\KVF3X.@^#
M-K%,@I"%/-6RG64C;F\.CJB%#=]HJ>!)&R/<V^&\=2J*9[US]S#/OC%`S@4*
M8L*/J_AD4E\D2JPAO^$&^@X-%S&HN]8I74G_`!EJ,<'?>SLT3A3ISAE8J6G!
M[N:J3.77X5`V/,8]_P#X93%(A];E[F43?*;\E*]L(^T-YD3!\ORCJO\`!2DE
M^]*R?T6_DCY?]7W6NS[BV&7_`(E[_5?)`?AHZ2RW/`<U<S1"V^Y50I\4ITJ;
M;=8^YVR,./AL'WP#L'GI_!9A/ZNZU@/T4?B(,/\`JZZBJ.[<^'U@?;V2]:<&
M'1WZ9SXC'YO_`(?ODG5CN%,;=SG*L.9,R7V<FI$7V#$"E$W5[TO"9=6*78`#
MIZ$A#??5/X3WFF!-#?*E*MTPOX9._%'<_P"I]PDO(0G5G!^RO@@YSXE&_P#5
M#UM'EFH'XX^DG;G[Z>*"*H8G[CL/<8MNJJ9@VN-PM\@^42(4OH^HTOM#NC!L
M=4?`4@=J)E`-^H?+5#HWBC0F=!?/$;&P+)^'.VYYIQ\5\UONW];J#NMN$[]O
MKEI&=5+2TK:`9XR515E*M0`^=X043NCS,O\`$O8E3!91'#^=F+,_0)3ML,+K
M.RAOLKZ,2YQM.KE,`?(`'\?(!UQ/\;J(S_J=2T/S6S/S*:,<`U[HO7"_#0J^
MZ:J'!.8-U`2>B;@KV0?.#TQX'[M7=IPB4JG(_MCR$[%-2_Y=.4*'R/561DT!
M+[TN65*VRE"`(%'?;U"E\0\=O'0\0.(=K.>]6$J9&U39<'EP2XG^=A'(<D')
M!Q#)3PFXP-4U8H]QFM=H*A<SZ*?"*K<[U8@G;A%>,:?$;\+9U9")S#2,VX'G
MDQ!&63L5/):H1@Z``!9--U4W;^Q+)I*;ANI$H&V#<2!OMJYT/&?3#J@U<VJN
MCJ/G!;96$]I1FE/K&S;*(UU=[J+F`MC9K=!W'3NI;8K%LL51IGEIW$IJ4H82
M2,>[4K'YT92<)<_>&?(I5HTP_P`CL6VV8?>D+>LA96D-;CBL(E2*-3GC1EA(
M8Y_J@`M@'J\/,=9W:M7:8ODO95=3O+/S0L!?U5$*^"-->(G+'Q^X4H6_KS2=
MYH:!N>:H]76]2B6)_K+'B,'#'!9PB\`@@8H&*8IBF`!*8H@)1`?$!`0$0$!]
MNLC'5LB"2"DD$2(\\>>JQ2&D(:0AI"&D(XW#VA](:0AN'M#Z0TA#</:'TAI"
M'4'M#Z0TA'`G*`"(F*```B(B(````;B(B(^```:;Y;X3EB=D?D05A@;1%,I^
MM34388.23,K'S,)(M)2*?(D4.B=1I(,55VCE,BR9BB)#F`#%$/,!#55)4@R6
M"%=!PCBE2%":2".J/V.H/:'TAJD<H;A[0^D-(0W#VA](:0AN'M#Z0TA#</:'
MTAI"&X>T/I#2$-P]H?2&D(;A[0^D-(0W#VA](:0AN'M#Z0TA#</:'TAI"&X>
MT/I#2$-P]H?2&D(;A[0^D-(0W#VA](:0AN'M#Z0TA#</:'TAI"&X>T/I#2$-
MP]H?2&D(;A[0^D-(0W#VA](:0AN'M#Z0TA#</:'TAI"&X>T/I#2$-P]H?2&D
M(;A[0^D-(0W#VA](:0AN'M#Z0TA#</:'TAI"&X>T/I#2$-P]H?2&D(YWW\M(
M0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$>ATY;,FZ[MXX0:
M-&R1UG#IRJF@W;HIE$RBRRRIBI)))E#<QC"``'GJBB$@J40$CIV1]&F7:AU+
M#"5+>60$I2"5$G8`!B2=P$8;>6W?&X9\9)=_1JQ+S'(7*K4_NHTW$1&TO&,W
MYQ53!K+7%10(!%=!5/99NV.Z=$*(#Z6XAJ,]2<5M+V!TT;*U5MS'^38`5(G<
MI?HCLF3U1OMP/]W1Q]XO4#6I+PPQI;13@S>M7,J:<4@2)4W2@>,4J![BW`TT
MH_/C'^AEWOL=Q`QY+$-.@^#F"Y=5-%C.6)-.(L[F#>I;^_\`VU9HM[;YI,I`
M$WO$1$L`(;ZH'W\1Q%-PXMZS'B6]MNSVE1P*A]H4G?-0)/\`)0.I6^-GG-"^
M[=Y5Y4FNKA4<1N(["25LL$NTZ74GT/"8<12M'_LZJI>F,<O15#&7P^5%M<VG
M=^;_`"FROR9N:O\`ZFWLD@PC$3G$#*('L-F>V.S2+553Q`B(1X%Z0``V#5PH
MN#M%4N>M:KKZFXU?6LA(\JBI7U<L8=J_WH>H[+;CI[EWT99-(Z?'SU,(6X0,
M`0Q3H8IVU`;2KQIS,97,1=LS@;@]%J6A<7\5@]9IIE),6N`3OLT=5/8?>C25
MU4GETG)SAU"9+T]C?>@``&TB6_1>E;7(TE#3A<I9E)"U>=>8^:4:4:YYO>9;
MB*XLZEUC>_`<)FU3/FB9D?F^'2>""G=)6:8VDQ>]&QT=$,T(Z)8,HN/;$!-L
MQCFJ#)DW3`/JIH-FR:2*1`#R`I0#62(0EM(0@`-C8!(`>01KO55=57OJJZUU
MQZI69J6M2EK4>E2E$DGK)C[#J)IEZE#D3+N`=1S%*7<?``W,(!N.N9(&V/BE
M*EF202>J/`CENJ;H3714/L(])%2'-L'F/24PCL&J3$Y;XY*:=0,RDJ">L&/=
MJL?.&D(:0AI"&D(:0AI".!W\-OT?JAI.$4&REQ=XWYL*Y_.U@K%&05W8#Z\C
M9Z)79.9$=_$23BK#[80,._B)%RCJU5MEL]S!3<*5AV>TK;23YR)_#$E:-XQ\
M6.'I1]R-27JUM(V-T]8^VUY60OPCY4$1BMSC\/MP'R@5U)8\AKK@"U&.9U'2
MF/;(]DH9C(["=%T>NVA:4,*:#@"J`FU>,Q`2_5,7Y,`N_"'2%RFY2MN4E3\U
M3:B0#TA*IREU%)C=#AU[T'F7T<44FJG[?J>S`97&ZUA#;RT?.2'Z<-R)3AF<
M:=Z2%19FKP1[V/"8WVKQ6Y;(\DZ1&"JY#'F0)15\]<,F8"*3`L#D5>230(JB
M`=*$3-(*"<!*7S#JQDZ2XGZ7[^G;F*VE3L:>[V`V"3A)F=G=='9LB?D\R?N]
M>88>I\9]#JTEJ-Z2?7:)L(0E:OGE^A2V52.U=32K$L3A.50<2=_];&]@:8K[
MB?&K(?'C(#`2,9FVP4!+O:TH[3#I4?N:C)I$LL8W7$!$I&:DL4H%$0.(#X=J
M@XP>SGQ;]:T#]#5`R+B4DMSG*>4R6!UR4.N4IXKKGW8C6K+6O6?*OJZUZITR
M[-;5,\^TE\).Q":ILFG<4!*9=33;?1!&.?\`P]G/$&?JDRO.&<C5/(]7?HI+
M)RE6F6<F5#UB`<$)!N@H+J-=DWV.BN1-0A@$!`!`0U,%MNMMN],FKMCS3].H
M`A2%!6WIEB#VXQYC:[X<:[X8WMS3FO[576F\M*(+=0TIO-(RS(41E<2=H4@J
M21(@R,58U<(PJ&D(:0C\_2$-(0TA'`F*4IC&,!2E*8YC#OL4I"B8QAV`?`"A
MOI^CO[8HHD"<01.^7\1R>XM[SPV[?=E?QU?4/*U#,O)./!U&R<J5%16/G*/B
M,RI4'C%FJ8JB#^;$"*F+U)M0`!%74U:)X>E(1=[TD*5@6VSCUYE2V[I)\\1S
MJ75(3.AH#@?24=XZ.D`^0G=@9Q5GX2GN&#,5J_\`;?R/-=<C34IC+O'!:0<B
M91U47SPBV3<>L?6,)E#UV:>EFFJ11$WNS]UML1#PZW%/3I:=3?V4I"%D)<RX
M`'8A0'1+NGJETQV-%W8O-&A?/V@!(_&-F_TI3Q4%'9*)L>H>QVD2/X8>2,^$
MQ@K;^$X:16&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D
M(:0AI"&D(:0AI"&D(:0AI"&D(:0CZD/O!_=#^L&D(]VD(:0AI"&D(:0AI"&D
M(:0AI"&D(:0AI"&D(:0AI".-_/2$6&<Y^XGQVX#4;\HLL3Y96ZRS1V>CXGKK
MAJO=[<Y;IB)#E:&.)8."!<2D5D70$;I]6Q?4.`DUB.K-9V71])ZQ<5YJE0^S
M:3(N+(ZMR=DU*D!&RO+ARJ\4^9G4?LK15,6-/,.)%7<GTJ324J5'$9O\L](%
M26&YK,N]E3WHP50>,^Z%WI)!&R9?L$IPMX9+J'"/I\&C,1TY=X9R9-3=.)<K
M1TI<S+(CL#Z2%K&;;@F@?Y8G:M^O^*"P_=EKM.EYX-HF%N)GO&"E3&]65.V0
M,>D%QU=R=>[]I56G0M*SQ`X_I`\2J>+;C-(ZF8Q<2%MTDC+[)CQ*C>MQ.[-Y
MQ([7O#CAK%,2XSQ9$SUT;D`[S)U_:LK5>7;HP)F46:2#UK[K!(@H01338HH>
MF4PE$QO$1E33FA--:7:2FW4R"^-KK@"G"=^)'=[$@1YV\<.<7CUQ[K7/O=>7
MZ73JCW;?1*73T:4B<@I"%9GC*693REYB)@)V#';\0;SDFN/F!*UQYQK85X3)
M>>SNE9^3B7SIC.UO&,&NB,@Y8.V1T7#%S99<",R*E4*<$$UP#P-K$.+NIGK9
M:V[#;UE%?6DYRDD+0RGTB",05&2`>LQM5[KOERM_%'B75\4M74J:C26F0D,M
MN(2ME^X/).1*TJ!2M+#4W2DI(SJ;.Z,'_8YQ9FOE)S3K5@L61<L2&*L"-T\D
MW)5>\VIQ#O9U!04*/5WH+3(I*!*RP'='2Z3E4;L5"G#I/XQGPSM=?>-5-N+>
MJC;Z-/BN3><4DK.#:%!2B,<5$2V`;C'HE[Q;6?#W@UR_5EKM5JLC6M-2J-!2
MA-)3I=0TH3K*A$FI_9-2;"I@A;R%),QA/<_9_N#XZVL(W1^:",3_`#\[OG&/
M@S%RU=/,M<L9V(W6)%8BI\DW7<1[_P!0&Z:U[G$@<,ZFQ05ZS*)*=;TX)&(1
M'J$!U@&K>(=CTNE5,#ZS>2,&$$3!V3<5Z+:1OGCN`F1&[/+)R+<8.8VM8NJ*
M==DX;E0+ESJFU)#B)9B*-DY55*R)`*$FDY@I3DL(C/PUC[J_>PR^UEZS,6?&
MN'V$D+0DM6Y2S4;!V.V:*QRKF,^8ND7]WM"**A@.!3.72IR=(%1+X!"+;NO>
M)]R\1E;C5N!D%-K6W2LRVR4DI6\O=@98RPE'KO<+1R5^[VT(NAO+%)=M=NLY
MRT^W3UEWKED#*,BTE%)3DB8F&VT@S)<.)E4\#^W-0N$T6K+FR-D[,F6IR#;Q
M-IR!D&Y6&38`D"OO3EA5:D[DW,1`QZCD"[G,5=XH"9>I4`W+J>M(Z,H]*LE0
M?J*JXK2`MQUQ:IRW(220E,^TGICQ<YD^:W4G,+6B@1:;/8-#4U27::BHJ5AM
M<Y94KJ*E+:77EA/S04-)*C)$\8R-:S2-4H:0AI"&D(:0AI"&D(:0AI"&D(X'
MV?H\-(H8I/EK!>'<\5U:J9EQE3,E0"R9DO<;;`L986X&^^/'O%T1?1BXC_LC
M=5(X;^`ZZ%QM=NNS/JUR8:?9.Y:0KS3V'K&,9MH?B1KWAK=4WK0-WN%HN:3/
M/3/+;G+8%I!R.#J6E0ZHCV9R[(64^.5ED<_]K#.ERQ==HU0TTOAB=L;C[%LH
M,U1=%@XJ<.)6,BU4%50J;";170Z``H+@8>K4,W7A56V1]5XX>U;M+6#O%A2C
MD<E(Y0=A'4L'HS"/4?AS[Q+1G%>T-<,><W3EOO%@>'A)NK+`\6GS#*7G6<5H
M5@DJ>I%(7,E7AE(E%5N%O>L=/\B$XM]QBA#QBY#Q[A.*1M<VR6K-"L\@J<J#
M1"4;21SEJ+Z17Z@0<`NO%.-@Z%B>6N_I;B@MRN^[VMF/9]\!RA2AE:<.X8DY
M"9X&90=RHPKF!]WNS3:6/&3E4N7WPX7.(+IIF5BHK*=L`J46E-@>LH;3(K04
M(J48S;5MB0B@JDNDFN@JFLBLF19%9(Y54EDE"`=-5)0@F(HFH00$I@$0$/'4
MRI((F-ACR[<0MI9:=!2XDD$$$$$8$$'$$':-T>W58X1^?I"&D(:0CH65,EU#
M"V-+[EO($JA"TK&U2GKI:))RJDDDWAZ_'KR+O8RIB)F7630]-(F^ZBIRE#<1
M#7UIZ=VKJ6Z=B9>6H)`ZSA'S>=0PTIUST$I),]TL8U`',Z)R?E6WSO/63Q`C
MC'!W,S,N:+)AM2&8)Q]8<A7+6JUG8B-:($(FT48'<)GW$"@Y$QE"`)=]ML]/
MO4U-3MV(/!=92LI"P93&&TGKV#R1!EYIWUOFN6V4-N$]G3*?2)R(W&*.<9.0
MN0^)O(+$7([%;\6%ZP_=8FY1&RAB-I1NR4%*;K<D!=@6A[1!.'#!VF;<IT'!
MO#RUWKM;F;M0.VY\!3;J#V@B>SKGYC'1MU<[;JI%4T9%)_'^'DG&XEXO<B<>
M\M>/6(N2.+'I7E&R_2HBX1!14(HYC%GB/I3%=D>@`*26K<T@X8.R[!TN&YP]
MFM1;C0/6NN<M]3,/MK*<>C:".T2EU1/E)5(K*9%2B1"T@]AWCM!BO6NH1*.R
M8:I"/+H-X#TB(#[`$=4!GLA#H/\`@F_>C^UJL(X$!#S`0^Z&VJ3&S?".-5G.
M$-(1R!3#Y%$=O8`CJ@,\.B$<]!_P3?O1_:U6$<"4P>93!]T!#3;AC.$<:;Y;
MX0TE".1*(>8"'Z0Z83(Z#".-(0TA'ETF\^DP[^P!_:TF!M!,(=!OP#?O1_:T
M)$IR,(=!_P`$WT#JA,H0$A@\RC]&@(,(\=5V;80U0&9EOANF<,8\N@_X)OWH
M_M:K"'0?\$W[T?VM(0Z#_@F_>C^UJD\90AT'_!-^]']K580Z3_@&_>C^UI%9
M1XB`AY^&J`S,HIOEOAJL.S&.0*8?(!$/:`#JDX8[\#'EZ9Q_O1^C;]?0&<(^
MA(!*40-X?6W\?9L'CJL(]ND(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0@.
MD(QF=S[N*TKM\X-5L8@PL>:[V1]#8<Q^J<QPD99(A2.[3/I(F*NC4:S[PF=<
M0$JCM<R;9+Q.=1+"-<ZRI-(6HO\`=7<W00RV=ZAM4H#'(B8G+%1(2,3&W?)W
MRJ:AYH>(PM7VM)P\MI0[=*T"61HDE%,R2)*J:B12@8I:0%NKP2E*\;O;N[5%
MLS%<?Y?G<M.KEC-&2B,+?3,5W!NHK&4IHX`KJ#D+="+`1D5^P8>B$;!E2*SB
M4M@4(9<-D\)T9H&HN-5][]<?UB[/R6VTO$-C:DK3LS`2RH'=0,.\J:HVRYJ.
M=2R:"L7_`"S<HP39-`6A2Z:JN5*0'*I0[KR*9T344+7G\>L*B[4JGD4ELS7)
M/33(D1--,A4TDR%(FF0H$(F0@`!2$(4`*0A2AL`!L`!J;=F`CR34I2U%;A)<
M))).))..)WGK,?)+RL=!14G-R[I%C%0T>]E9-ZN8"(,XZ.;*.WKM8P^!4F[9
M$QS#\@!K@XXAMM3BS)M())Z`!,GS1V:&BJKE7,VZA0IRMJ'4-MH&U2UJ"4)'
M6I1`'68UD_<,Y73/,GEEEC-+R2=/*LYG'==QHR7./HP^.:^Y79UMJT1Z4_1!
M^D4SU0-NHRSDPFW'6E>I[^K45\JKX^2:8J*&?S648)`&_,>]AMF.R/U]\K/!
M2@X!\$K+H"G:0B\(ITOUZQM=KGTA=0I1QGD,FD[LK8D)1+^[6^.\5=KSMU,,
MO\G+%`XIG<J."Y.O;ZP'!*8*G+H)(T>F,HY('$E,3+2!!(X,VB:J@++JF$H%
M`YBS_H6CH="Z-]JZ@6BGJ:@^,\5'$9OU;8`F5%*)`!()ZH\)^<K56M><?FK=
MT)P?I*F]6VRI-OHT,";4VR3652W.ZVVTI[,/%<*1E0A,R2D'%#S6[[?(#E+;
MF_'[M]U>YTJ$LS\]?8VB-B_M#,^1%G2HI$3KL<T3=A2(U1+81,F91X!!,=1=
M(FX%P+4_%.[WQ\6C22'667"4A03FJ'9&4VTXAM/2I6S:2D1NQR^>[:X8<&+(
MKB?S/UEON-QI&O'73N.9+51!`F2^XHI];<2<.\`U/*E+:U2)K9P"^'GDI*3;
M9C[@DFK)/7SEO/M<)P\^N^?OY!R<7[IQE:WHG.H^<*N#AZ[%DL<%#`H"K@X&
MZ=7/27!]QP^T-8$',<W@(43F)WON;5G$S2,)[28COF=]Z524M(O07*^TEIAM
M"F579UD(0A"0&TBW4Q`"``.X\Z@904Y&DD3B5;1:'2\95.$HN.ZK!4JFUQF1
MC!UFMQK:)AXQF0=RI-&+1--$G481,8=NHYA$QA$1$=3S34M/1,)I:-"6J=`D
ME*0``!N`CQ:U)J;4.L;W4:DU56U-PO\`5K*WJBH<4ZZXH[U+623A@!L`D!("
M*<Y"Y/<<<2O@B\FYVQ)1)8%10/$6?(%8B)=-4"B<Q58MW))OT@*'F)DP`-_:
M(:ZE7>[10*\.MJJ=I?0IQ((\A,XRW2W!SBQK>F]=TAIJ^7*BRYO%IZ*H=:(V
M3#B6R@^11,4U#N"<'14%$.6?'\52^(I!E&IBH`>>XD"3Z@\/FUT1J_2Q5D%Q
MHROH\9$_-.,M/*_S%A.<Z(U/DZ?9]3+S^''L'G]PB#SY78##[N3JJ'_&6N7W
MKTR!,U])+]JCY8X_\L7,1.7W)U-/_P#GU/\`JXX_E_\`"'^E?@/_`%G53_.6
MJ?>W3'_["C_SJ/EA_P`L7,1_[)U-_P`/J/\`$CZ&O/3A2^<-VC;E7@)1=TLF
MB@0<HU%(IU53`0A?45E")%`QAVW,8`]HZY)U3IM9`17TDR?Z5'RQ\WN6?F%I
MVE/NZ*U,&T))/^[JDX`3.`;).&X`F+JF+UG),VDC'.VS^/?MD'K%\S72=,WK
M-TD1=J[:.D#J(.6SA!0#IJ$,8AR&`0$0'5]2M*DA:2"@B8(,P1T@]$0K44]1
M2/KI:I"VZII90M"P4J0I)(4E22`4J200H$`@@@B.OW:\TS'%9E+ID"UUZE5*
M#1!Q+V6TR[&#A(Y(YRHIF=R4BNW:HF664*FF43=2BA@*4!,(`/RJJFFHV%5-
M8XAJF0)J4LA*0.LF0'GBZ:>TY?\`5EX9T_IBBJKA?*E65JGIVEO.N$`DY6T!
M2C(`J4922D%1D`3%!JYS:X?V^=B:Q5^3.$9VQ3SU&-A86-R/5W$A*2#H>ENQ
M9-B2`J.'3@_U4TRAU'-L``(B&K2SJ;3K[J&&*ZE4ZLR2D.)F3T`3Q/5$DW7E
MYXZV*VOWB\:1U%36JF;*W77*"H2AM"1-2UJ+<DI2,23@!,G".VY&Y/\`''#\
MJG`Y2SIB>@3JA04"#M=\K4-,E3$A%"*JQ3R02?HI*%.`E.=,I3;^`CKM5M[L
M]O7X5=5,-.="W$I/F)G%ETGP<XL:[H3<]&:;O=TMH,O&IJ.H=:)F1(.)04$@
MB1`)(WQ3G^7_`,(?$/Y5^`_#P'_G.JOA]W_=+P\]=(ZLTP#(W"DF/^U1\L96
M.6/F(/\`_B=3?\/J?]7#^L`X0_TL,!>([!_SGU3S'R#_`'R\]4^]FF-GM"DG
M^U1\L5_Y8N8G_P!DZF_X?4_ZN.?Y?W"+^E=@3_6;5?\`..N7WJTU_M])_G4?
M+%/^6+F(_P#9.IO^'U/^KC@>?W"(!`!Y7X#`1\``<G54!\1#R#[2\=<3JS3(
M,C<*0']JCY8?\L7,3_[)U-_P^I_U<5V7R[BMMCY;+2V2:(7%S9@,FOD0+7"'
MI:<>"A4/?/RF3>FAQ1%P8$P$%AW4$"A]80#5S57T":0UZGFA0!,_$SIR2Z<T
MY?#MB-6]#:U>U0G1#=IN1UBMSPTT/JSPJRN4\OJY0'9Y1FEE]''9C&*?F?0>
MV%W*ZVSQM8,^8'4S.]3&%Q+D2KWNHKWZ$GG(J*1T2S*6134L40_>B!58I43%
M<";9+H6Z#!@.IZ#0VMZ<4%35TAN2NZRXE:"XE1Q`&/?!WH,PK'"<;J\`-3<X
M?*/=7-6VW3.I!P^;5XURH:FCJ11/,ID''%3;(8=0C%-0F11+OYF\R8L-X!\S
M,]]OKDBAVTNX3-+N:L\/%0O&[,TE[RYBE$7[[[.JT;^4+H`5?4:R]96K15P8
MRL)()>Z+"5(1,EBFC]1WC1UZ^X^LEYJ8R32OF<B"9)25':A6`23BA7<4<03L
MKS.<`>&G-#PG5S<\KM.E%Y;#CM^M2,J7`I",]2OP$X(K&)%QQ*`$U;"O';!6
M`%RC]O#Y//\`N>>IVW2CQK^*/AU3,>KSB*R5T?%\L<_5]H_O?[NJ9^I7X>6$
MCT1QO^C]G[FN07/8)X?AOCB<!B9#KB*I\2+R.O.45^-G:#X[OEG&9>:MZK8Y
M'+%**&=5_%+>93*W1D"H"(I,Y)TT7D')3[?Y+&[_`'I_&2M`T#=,']4U@'JU
M&@Y9C`KEMZY#`=9$XQ?4-4MQQ%L8D7%J!($NGNI.R8)[Q_-!(B_;G7VA,8YP
M[4,?P-QA"1T?8\!8[@9#CI*BF@@Y:Y.H$,?T`7>'(0Q$\B"9VR?',(%,9]ZQ
M]S)EU9+-JE^AU.+R\?LWEGQ!CZ"CN^B)$3Z,([%QLC3]F-`V)K2)IGB2K:9G
M\[&-5C,Q$K79>5K\_'.HB>@)-_"S,4^1,W>QDO%NUF,DP=H*`!TG#1X@<AR#
MXE,40^36TJ%)?;;>0H9")I(Z#(@^4?#.(1=;6RZIM0Q!D1^'X&)HWPF?<2_)
M^U7GMSY+G.F(N)I?*W'=1^X`$F5I9MO><C4%D*H[)DGHQN$PT2*(%!PU=])1
M.OXPUQ4TXI2$Z@823D.5WR^B?(<#V]42)H>[2S6QU7=.*)_E='E'PCKB=[J$
M8DH3W[8;[>(;>'M\0U0B>$5B/GW+>V_RAL,%R<Y5X`[HG,3"]AB:A:\JP^&6
MEO;&PK$H4NKKR[VKPD;'-F,Y",9-M$J="A'*@IKJ]0E,7<-9S8+_`$#:Z>VU
MU#3NLE:49R._WC*?08QBZ6JH*7JQJH<"@E2@)J`$L<)$>3;$`+^M>[GI&K5V
MKSCY0)(/B&49K*9+LQ&[HJ*AV[A1FLHN5)R1!RD9,XD$W2<HE'Q`0U/ITKIR
M63U-C/(&8`V'>9C#HQB+%7>ZMDI+SLIS])73LVX81*J^&`[LF8\X98S!PXY8
M9EN.5K?;(L<L8*M>1IYS.SAEJ\V189"Q\UD7ICKJ)#&"VEV:'5L0J+TP>S47
M<3-*TM*RB[VQI**9,D+R@`8XA6'6)'MC.='7QRJ4:*K42X<022<?*=XG+LB:
M_P"P-]Q]FH;$PD9O)$@;XY`!'Y//P\O/?P^70]WTNC\/+`]'3&OQ^(C[Q'(]
MOS1<8"X=9TR7BC''&B.)4LE6;%]BDX%E;<Q60A)&5B9F4C#@@Y+4HPB;5%$R
MG\8,N(%W)X3MP_TE;U6P5MV90X_4$J0E8![@V$=NWS1&6J[[4(J_`HUJ2A&!
MRDC9M.&Z>$YRP4(P;8T[F/<^R5DG&V-6//KDE%O<CY!I=`:2KG)EE<-HMQ<K
M)&5Q&2<-DWA%7*+`\CZIDP$HG`G2`AOOK-ZS3>G*6D74^I,S0A2C)(Q`$Y>:
M,:I+M=*FI2P:AT)5UD_CC9-\%.WOE?B%:IJZ90Y_<K.74G8:6SK+RKYLLD<^
MH,)*)O4Y!U9*O!-6974?(K&`R!15<+&!N;I$1'QUKI>[[375I++-&Q3(0K`M
MCO';M\^.&Z)=M]N=I'"ZZ\XZI0V*)D-FR9/1T[XR=^>X?-]WQ\O`/E'Q^<-8
MYV?AV1=HP0=Z/O:8][7=0:8\JM<=Y#Y7Y'K#F:QK57T?(-*/5X51=S%DOUSG
ME$4FLFR8R*)RHQ;%15RY63V6%!/8YLVT?HY_5#_BJ.6VMJDM0]([,`-W;+KC
M'-07]JS-2`S5*AAT#?C\,A^*,+GPUG>0RCE?D!E;B5R_RI-7VT9XL$[EO#=T
MM\B*RJ.0E^MY<\<1WJJ$;QD+.1R?O<2Q1`J#=5J=!$@>L`:S#B+I"GHJ%JYV
MEH)0PD(6$C`IW*)&\2D9[9SGA&/:2U"[5U*J2K427"2DD[#_`'?CE(`1."VV
M_5\/T;?+J&9XX;(D.?1L,<_K^W]'AKD);MIBO5U1@R[D'"#D^]KO)_E=@3N<
M\O,!R5<QC9\F0V%Z]-5]_AF/=8YI3F6=1+&)7BR3<:UL984WJ'1>%,FX7%0`
M$/J#E]@N]OST]KK:"G?070DK/IG,H;^J<8[=:&J"7:YBI=1E03E!.7!,\)$?
MA.-?,^[S?=4ED?2>\\N1GIF+L)&][>L_(?'ZS4J)Q'Q\!W`=;`MZ,TP@@IHV
M?*D'R?WHBM[4%V*BE3RR1AZ2CO[8D[=I/@_RK[GG"R.Y0Y$[L'/O&EUE,DY$
MI:$-4LDHOZNFQJ#UDU:/@;RZ"\@HN[5<&%8/7*7<FQ0+YZB_5EYMNG;VNW4]
MMHU-)2G$IQQ![8S:PVZHNU`*UZI>SYI2S*EL!W*'3'1^X9Q>[[':MQ])\C<*
M=R7-7)K`-/.BZO"LTX<.KIC^+$Y2%GK/2K`O9H*Q55JJ(%=NVABJMBFZU$/2
M`YR_6P731FIZ@6ZOHFF:Q0D#L"I_DJ`&/D[#%;I27VTH-52U"EM;\3("6_,3
MUXDD=,ML=0[?/Q9V4(.RU^@]PZDPEVHL@X;L'.>\7PB<#<JL"QDD2RUKHS#:
M!LT0V#ZRYHU-D[3()CE(N(`F/;O_``J:#2G[$M27I$AM4B#+H5M'EG+X8Z=J
MULX74LW)().&;8>C=@>S#MG$ZG'V0:5E2D53)F-[-$72A7F$C[-4;5`.R/8>
M>@I1`KEA(,7!.CJ(JD<-R&*4Z9]R'`#E$`A"HIW:=Y;#P*'T&1!V@C;,#S1(
M[+K-0A+S)"F5"8(B,]W@N#O*?!^!.5W.7!G=(YJ5"0I9GV5$L)/;LW5Q>PAG
M\\P:NZ=5B136-F8%C'HR`F9&%9<I03`ARB!NHLD:2O=NJ;C36BKMU*I#G=*@
MG$F4\Q)G\$HQ2\VVKIZ=VN9JG01B$DF0F0,)&75B(A`%[LW<SV`?Y=7)C<WE
MOE*Q[!\^X._(-_U=3:-*:;![U$SL$SE&^7Q1&9OUVG+QW!([<Q[8F*=K_MV<
MV^9W#O$G*O-W>"YQU=SFVONK96*3BV\D9,ZW"!+R,4R3FY>RHS+F8EEPC154
M!)-N@GU@0.O83##FH]06FTWAVW4=LI%I95E*EI]+`'8)2\_3$BVRTUU;0HJ'
MJQX*5T$SPPEB9;NB?7%I_>CXQ=PKM?8#JG(O&?=QYB94JDODB%QQ/U3(%O<1
MTZP7LK5\K#R\1,5Q5FS=I(K,#$<(KMRFZ#@<A]RB4UTT=<K+J2Y&WU=NIFU!
M!4%(2)`#=(C;CUQT[[1U]LI14TM2X09SF53P25;U$;$D"0&)B-&\[K'<^9+J
M,9#G#RC8NTBI^LT=9+M+-TD"Z)%T!.@NX361]9LN51,3%#K(8I@\!`=28C3&
MG%";=)3J"MA"1(GMEMC"EWJ\-DDO.@=9^&4XF#?#]=_4_(<E?X4\W+HG^?Q$
M`C\,9GL;E%$F9FI`$R--MK]42(IY)9D`0;+'$H2Z1=M_>2[*Q#KS0IMJS=;2
M@^J*)*D"?=_.'4-X_%&?:9U,W6)31UJI/C`$GX"3MGN/D.Z<O\?J^'B'W0']
M/Y/;J*`1+''\/CC.`)X2!(&/5\L8SN;'`[.?*&X-+OA_N)\K>(#B.I1:RUIN
M'9.OFQV^FT'K]XVMDY!2,<,@[D%2O2H.`1=H"HBB0"F(8.K616:]45L:\*JH
M:>J25S)7/,!T3_N2BUUUOJ*IT/,U#K4AZ()D?("/PZHAQ8%J'>PS#W3KUVQ+
MEW(>053E,5.+#/92RM"WB9DV#7%D1'Q<I'7.MP[IV@HJ[N3*RQ:3)LN;9JYD
M`!;<J1]Y;N%5I*DTJG4;=O8+CH`2@[E';YI8]D8%2,WE^]*M2ZA>1"C,S5LE
M/I&X[B-T3J^&?&FQ\4\/'QA:>1>;N44NM:Y:T+Y-SY/,K!=BEE&,0S"NM7;!
MDP;-JY&GBC*MD`((D5<JB)AZM0M=KDBZU0J6V&J=.0)RH!"=YGCO,Y'L$2+0
M4:J%DM*<4Z2HJFHS.(&'8-T79!Y:MD=V.=(0TA#2$-(0TA#2$-(0TA#2$-(0
MTA#2$-(1ZU5$TDE%5E"))))G4555,4B::9"B8ZBAS"4I"$*`B(B(``!JA(`F
M=D<D(4XH-H!4M1D`!,DG``#>3T1$\X@5=3NQ]UK+_,:_L%);CEQ8DF=7Q)6I
MO9U%OIB)5=-:&U^SUCKMNA%1N[L\@F41($BZ;A]8AM@@'3K/\0.(%3J.J!59
M;<0AE)V*6/0$MD@"IPX&:E)Z(]L^.UY;Y)>2JP\!=,.ACBMK-E=1<GVNZXAI
MU*55JLX`5,@MV]@F1\!MTX*$XEB``AMX>'A^D`>S;;PU/WX?A_<CQ*[=L>0^
M0ZK"(_7Q"/,<N">*S;`52FBM,D<CG2T&_29/@1DX?%\6)%[9(*(DW6(A/*F2
MBR&'IZRK*[;]`ZB3B[J$VVQILE*O+75ZLIRF2DLIQ<5AB)B2`=DS*/3[W7/`
M57$CC0OB7?*?/I32J`\@K1-MVX.3%.@$X%3(S5!`!D4MSEF$09JA/EJEJK-H
M-#Q-@+6IZ(G0@9Y%5S!3!HA\@_3C)IH@LW6=1;PZ`$73*H3U$A,7<-]:V-*0
MRZVLI2M#:TJR*'=.0S`(P.68$Q,3E'Z.+Y;%7RRUEG2^_2^MTSC/C,D)=:\1
M!07&B0H)<3/,A1!RJ`,L(R]<>,)\Q>^-R%L;Z^YD8LJ]0F\8_M4O-.R%@<<U
M>5=NT8BNXPQA&+-6Y0,+94J)$R-VJ0$$R[@5!`JF;6JUZDXF7IQ3]2`E@`K6
MJ10TE1FE##(P)EL/HCYQ4<(T6XI\0^`ONZ.%E)3Z9L+KETN:G$4[;0^VKZEI
M"2Z_<+@X"K#,@K4HN.*F$MM902B91PC[;G&7@C56\=BBI(S%]<M`;V?+UJ;,
MI'(-E.*GJ*$/)$;I(PT64X[)LF1$&Y2@`B!C"8P[%:6T58]*,9:!O/6J'VCZ
MP"ZL]:MPZ$ID!T1X%\P_-EQ?YDKRJJUI7*8TTA>:GME,I3=$P)2$D%1+KF]3
MKQ6LG9)("1?FY<-F35P\>.$&;1H@LY=.W2J:#9LW03,HNX<+JF*DBBBD03&.
M80*4H;CX!K+%*"05*("1TX`2WDQK4TR[4.IIV$J6^M02E*05*)49!*0`223@
M`!,G=.(4_=;[Y=_RG:K1@'AO;GM'P]!2"L-/YDJS]TPM^5'+7UVTFE699N=%
M6`Q\LJ;TTCH;.I-,@J'5*W5!'6MFN>)=;='W+5IMTLVE!*5/H,EO$8'PU#T6
ML9`@YER)F$RG^A#DH]W'IC1=EH^)O'NA;N.NZIH.L6NH0%TMO2N2FR^V00]6
M@#,H*FVPI61*"XCQ8M/[3W:PM'<1O,OD_+<S983C]2)EJC:)\3/#V')T^)C.
MEZC7)N0]0$TDR`!I5^455&Y%2IDZ5E"G3Q[0N@5:QJUU=<5HLS2^^HXK>7M*
M$J.X#]8H3.(2",8FWG:YSK+RK:=9T?H9BDJ>*%QIU&G9&4,6]GT15/M(D22<
M*=DY4N%)6J:$%*I5/+[MG<+7W"_,](JG'W%E#5I^*[?9J99JU3X>.LU=L-2K
M[V=82R%@3;!*K/':T=Z;M1550[E-93U.KJ'4[:@T1IES3%30L4=.RE#"U(4E
MM(*%(25!0($YS`F9X[X\6^!7-YS`4O,!I_45[U1>KFW77JEIZJGJ*IU=.^Q4
MOH96TI@J\,(2',S24I2&U)3DE(1`2XW7^J8PSCB^\7RB4[)=%B+9$!=Z->H5
MI/5JP5)^Y386%NZCG@>@+M"-<*+M%=]T'229_$"[#JK:*BGI*REKJIAI^GSH
M#C:TI4A:%D)6"DC=/,DC$$2V3C]-?%K3%ZUEPYO&G--7*NM.I'Z)SU2KHW5,
MOL5*$E;*DK0)Y2XE*7$8YVRM.^8V*L=VS.W-)QS&3;\-./7NL@R;/T3&QS`;
M>@Z;D<)F$0;].WI*`.^MN$Z"T.M`6+5024`1]BC9*?1'Y4JKF\YK*2K=HG-?
M:H\9IU2"/7GO22HI/SND1`.[ADW@6>YF9[<\9:A6Z5A*-N7Y-4J)J!")UAZG
M58QA7)BRP*"0%;MHBUS\8ZD&R:0%3*BY+TAYZU<U0+*YJ*K596&FK6EW*@(`
M"3D2$J6!(2"E`F6R6.^/TX<K-NXF6O@#IEGB[755PXAO4'K%4Y4S-0DU#BWV
MF'R>\IVG9<;86I9)*VU3)B=#V6JMD*I]MSCFSR,[?.)*4B+!9:^WD5G2SV-I
M%AL\O*U%D<[P`5!%6(<$<H%#ZA&[A,I?``ULSPUIZRFT71HK"2I22I`,YAM2
MB4#'$23CV$"/SA^\$O.E;US9ZK>TDVVBC9?8IWE-A(2Y5LT[;=2L9<"0Z"VL
M[5+;43MB.3\0!W$$\[Y70XEXFLA'V),-RAE\AR<-(@M%W?*B`BBK&'.V,9N^
MBZ`'4@'USD&246W`!0(.H?XJZK3>[F-/T*PJU4BINR,TN/\`Y)E@4L[Q_2&6
MU)$>KGNQ.5A7#71*N-VMJ0MZWO[(%"AU&5RCMQQ"P%24ARM,EG!)#"6Y&3BA
M'5_AY^'ZN9^3D[R%LL`5U2./D0+JKO)..47A7N6IM-5"O"BL8`26>5-H"C\2
M@(F34,B;P\-?#A-IU%SU$N\N-I]4H$R22GNJ?7L(.R:$X]().`B\>]+XZHT!
MP@IN%MHJ<FH-4/Y:A#;DG46UDA3\QM":A4F03@4^(!OEB;YCX?Y&8PSMDQ?D
M=2\B0EKFL@VQPI9[K%37V?;%5Y=T]))0%F?I#&6!BX:N"*I':KJ%!(P!]7;8
M,#O5LNE'=:@7QEY-:NH<.=Q*LKDU$A2%D%"AEE(`S`$;N<`M=\*-8<-K.UPH
MN%KJ++3VRF2*>D<:STP#24>&]3H5G86E22E0<0DDC?M,IGL?<-N(.>^!4%>\
MW<<L,9!MD;D#(\.ZN-QI,2_F5X>.FU730DE,/4>IVC'(N3$3.)NE)$A2>`$V
M":^&&F=-WK2B:R[4%(_5)?>1G<:2594N*E,D8R'R=,>,OO%>/7'3AKS+U.FN
M'FJ[_;+([:Z!Q-+2U;B&DN+:"5>&T@R27"D*(`FI9*I=Z,,O=0Y1\*)RTV3`
M'!_BU@2EU"M32D9:>0-?HL`%FNSV+.*+J/QU((-A"!IY7H'*>03,9S*$3*9(
MZ+<QBKQ]K:Z:6<J';3I:W43%*A65=0EI`4Y(]Y+1`[J)X%>U9$DD#;O[R8<&
MN82VV:DXG<Q6LM35]^JZ8.4UE>K'O5Z1#@FA=<@J^VJ2F1#*@&Z<DA86Z$EN
MU_MU]N?+'<*RP>IU(3U3&55.T>91RH\8F<QE7C7!MT(F*0,9)*8M\P0A_<V8
M'`I"E,LL)4R#U6C2NCJW5U?ZI2`-T;<O&>*`0@'8$C87"-B=@&*A+;,7-7S6
MZ)Y7-$^W+Y*MUA6A2+=;DK"7*AP2FXX<2U3-$@NNR,U$-H!6H2FO8Y[+W;OH
M.)4<5NN/U2O;D\0XCY3)5X8-IK)DF^=I'(XFRV84DEH=\5505$$V16[=N(`!
M$P`-M;&TG#'1=)0>H*H6724R4XXD*<4?RBLB<]XE@-PC\]FJ_>`\T^J-<*UH
MSJ>MMK/CA;=OI%J:M[:$D%+1IYD.HD)*+Q6XL3*E$F<0.\R77)F('>=>'=?R
M9:'>"H#.%F!6F*2:JD'+RE'G9*#A9ATUW!,'A&;8GJE)TIG6*!C%$2@(:NU1
MJ:`5FF6WG%6=NM7-LGNJ+:NXH]<I`@8*(F03'Z4M`:>T?KNGTYQXNEHHT<1J
MK3M/*K\,!YM%6RV\ZTE6W)G4<I5-029`@$B,H78#X6N.0G*Y#.MIA@<XLXW'
M0L'KND"*,)C*#M(WY'PY04`2+*0:9CRB@AXI*(MQ_OM9OPLTRF\ZD%S<0/9]
MO[TY8*?4.ZF?YB3F/6H=$:<^\YY@FN%O!57#BS5&36>K`IB25$+:MZ#_`%IS
M#$>+(4XG@I*W1\V),/>9X/1G,7B39IB$9HHYEP/'3N4,9S"#3U91^WAHM5_:
MJ(FLB)7(H6R,8@+<A1^K)MFI_(#@,T\2-+HU)I]:FQ*YTH4ZT=YD"5-@C$9P
M,",0H).Z/(CD!YBZO@-QOI*"XK4K0.I76;?<&BJ3:%.N!%-6$'NSIG%G.2,:
M=QY.TB6,W^M\M?\`4C_G/^UU/Y2_V]_(]^W/M`?MC\L?R;]]_.AU[^]?:_YM
M?]T/4V_WZ\?O/#6#_P`1*G^%_M*9]MYO5,TQ//E_7?YOO_2C;S_D5LG_`%#/
MN?X`_A%ZK]Z/!R#PO5?'R>SOR?"]?^QR_P"R=WTL8J=+\SN8C5Y),0[Q_9%B
MUFSUXU%!Y7)`'S`Z#A1(6[Q!7D*4`=MA+Z:A3`&QRB`^(:VT3:;80#[*N7G_
M`/ACPS]>K]AK:*?8?ECK3WF5S952(#/O8]D!)0%"F,<:L9/<NP^&ZV>WQ=_'
M\$!^<-=D6JUG;:;J!]*?^"F/E[0K22/7J'\//'3[%S1YV0\/,3ZO>^[*PM("
M'DI=TPAJ:UE9)XC&-%GAT6$<7+3E\_?KD2Z$D$"BHJ<P%(4QA`!^S5GL[SB6
MD6FZS49;98G?V1Q5<:Y#:EFOH\`3A+=NE*,%O;DR;F[E;S$R]W2LF=Q7@+QZ
MY!,9*1Q73$.445$N?M:O)Q+>/4LF.\7/LA5%[1J^WB$"-VK@[A583+*AYF,8
M<TU`Q0VRU-:;IZ&M>HY9E!M1DDSGE4N1"B3B1+<.J+!;GZJKJUW)RK8;?!!&
M83!FF4MWHC#J),HDJU+D9S7O<G"UNH]Y?M`V.V65ZWB:Y!UG$I)Z4F91\J"#
M!E$1;7DZ$A*OW2Y@*F@B03J''I*&XZCQR@M#;:E+M5Q2`-I<P2.D]P8>6,F9
MJK@ZXEM%;2J63L"93ZL9Q&2^)\[<4AQDY-5SEY3HUJ.,^5H"I?UH6./'PE>Y
M%1,>DM=/08BNZ&+C\C,R#--$U#B(NROR@)@3`=27PQU$FY6Y5I>)-13^@2=K
M>XGI*1W3+H3&'ZRM`I*A-:V.XYMD``%;3Y-_8>J(X&&LMWO`66<=9KQE,.("
M_P"++?!W>IRK<YTE6LO`/TG[=,PD,7U&KGTA263'ZJJ2ABF`0'4BW"B8N5*Y
M25"<R'$$2/FE\/:!C&'TE2JD?0^T2EQ)!V]?XHW"/!3EW1>=7%/#W)Z@*MR,
M,CUELXL$&BL55:HWB.`(^YU-X4%5E$EH:=;JE3!3I.HV%)7;8X:U(O-J?LMS
M=MU0D@H)D3O3\TCM$3];JUNX4B*M!$E#'J/1%W&K7'<B@G*Q#WGBUR8;"GZO
MO''W,J/I"'5ZGJX[L1.C8?`>OJVUWK82+E3D;?';_2$=6N_L3W[)?Z)C7!T[
M@@?D=\/&SY/4F`%WE/B#R=S=)S:C%$II*7P?8YN,2MK%4"B*SHE-F#I2J10`
M?1;G>''8H>$_KOBK9KL6]U9%'5,!(Z`N:LOG.'FB-:JUIJ[!ZTT!X[66?6"T
MCXC\!,84N-'("]\5<_XAY'8S=G:W7#MY@[K#"502(R2<>OTRT"]`!#U(RR0J
MSA@Y(.X'0<&\!UGEUM[5UMS]O=2"AU)2!NF!Z7D,8?;JMRW5;=2U@H&?F^3X
MNV-QSQNSY0^4N!,3<B<8OBR%&R_1X*[P)P,!U6:4JT*=_#/^@``DI`R95V+I
M/S2<H'*.PAMK4*X4+UMKWJ&HP>:44GMQQ\HE*)\HZE%93(J6L4K`/GW>0Q;;
MW/.:]>[?_"C-/)"5417L<!7U:_C&`,J4CBSY0LX&AZ7#-4P,19<PRSDJRH$Z
MA(BD8WD`CKNZ<M2[W=FZ$`^#,%?4A)Q,^O9VF.O=*OU.B6\F0<(DF>X]/8,2
M<#@(@9]R?AO8>)79ZX76_+*"[WDQS%Y06SDGGJR293?;RTG;Z+(3%<KT@LK^
M.$L;%RGO"B9MA3<N3E$!$H;3CIB[FYZJJ::G(]G4C`0@#8)&1(ZI_%$;WVD3
M36AEY29.NJ69G:$Y>[/`8GTE=*B3&"WBM_.GXO`'](_!N_S?\YU9V^G6<WO]
MTU)&SP%_HF,4M/[P:C=/J_?C^E_@EUIY+'"-@A^*/``$1V\M_#Q#<//80'YM
M_/5")@C\/P_O0,R)#;&N[[P[3._>?Y1<RLB<9HEM9N.':GQ@]JS>29MUW2F1
M[(2?(XRB%2=LD54Y6:4/$/G+5$QN@8N`ZBAZC@@&GS2+E'I"W4K%?W;C<G<P
MQP2DX"?1M&.\F(NU"BIO]4Z_22]6ID[2-N.,NHXGID`8BOXYR%;L57JD94QU
M-NZ[=Z!9(:YU">8+'1=1TW!O$)&-=(JIF*<"^L@'4&X=1#"`ZE.MIFZVE73.
M)S4R@4D=(V&?GC"*9Y='49TS#B%#X#CYOQ1MZ^V=SFIG<.X=XHY(5A=FA8)F
M(2KV4ZRW43,O4,I0"*32WPSA),"^[MUWFSQH&VPLW*8[B.^VINI+.]8+N[;7
M0<J5$I5TI.SX/BB=[3<$7.C34(/>([P_.ECY]HZHOXU8XN46R<V/YF7+OYN,
M&>A^C%MH'5QLYRW>E`V>.V?YXCIW']WO_L5_HF-,`3Q*7P\_D^7S]FMQ6YE"
M2=I`C7MW!U70%&-G+\*]_9(TOY\ZYS_4LK4/UPUK/Q+'_FQWJ0W^C^*)FT<)
M6).[O'XA&:[ET\H,=Q6Y'/<I'C28[;X2R8>XC+"D6.^PAJ,H#TKKU?Q7IG((
M``#YB(!K#[1XJ[E3IIBKQO&1(#;/-MZ8O]>I`H7BY^J\-4_-&EK9`0&R/I@?
MW<"%](JH_C/0V_$`?P#<X(B4!\M;BH`4V.X2HRE/?*4AY=D:_5:CZPLS^TF?
M//&7EGLC:%_#`+W5;M#X?_+$\B=JED3+*%%&2%43!1$[0I]D%8"KYQ978N00
MZ?J[;[>&M9^)"6AJM[PI9LJ<TM@5+$=HP[8FG2OCFTI+TYA1V_#\,XN[[X/]
MDOSM\?\`H4<?J6.`U:M&_P#JBB_:']$QWKZ)VAX'\D?I"-1\4?Q9/`?O0'Y]
M_'R^?8-;8G$R.PY?BB`2.^?PZ/EC;9=BMN=KVB.!22@E$PX0:K?5WVZ7-EL3
MA,/'QW!-4-_GUJ;K8`:KK`-GCGXA$^6`SM#)'Y)_2,8V?BX0_P#Y>USQ'^<O
MB[8`W#R9V(`V$-]A``UD?"XE.HU2P5X"OTDQ;M4R3;DI&S,K_1KBW#GCV+(3
MGUV]>*')WC7$QE=YCTOB3@_[1B4$F\=$<@JU$8SA%$JU-F3!)!&_L4>H(J24
MW%<1!LN8Q!(9.X6/6CE@U#4T-P4I=J74.#$S*.\<1U3W;L>N+77Z>;N=H9?9
M`]<#(,@-N`Q'7T_E;,"`1`EDXJUT&U/X:886&D7FE6!5H_CWB;R`M%2M4`]Z
M5454S`WD(>;B)%ON`ATJ)J$`2CML.IX0Y35=/W"E=,H9IB13([.G;$8J2]0O
MR,PZCM_N8=/1LP(C8:_#^]^1ERXAZ_PWY=V=E&\H*Y%IL,99%E7"+%ER!@(M
MN!2L7BB@D02RK#M$0%RF&WVLD47"0"H58H:_:ZT.[:7E72V))H%$E:!B6^O#
MYO5N[)1*NF-1)KT)HJL_UE(P/3U'KZ#*1'7.)7_B/B/[7E\GB`>6HOV@*$LH
M/X\/PZ8S29)(WQ$_XG-CJ_%9]PUR42]+7B=!%.`[[B+B"XWE(`?(.PE'?4H7
M4#^&]OP[WK)QZN^8PJA$]8/G\T_HHB64C]Z/W=OH*4-1A&:@2``Z(]ND5AI"
M&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"*.\B'3]CQ_SF]BA4+*,\.Y-=1ID@
M$52OV]*FU68I@`@(J`X(7;Y]6^[*6BUU*V_3%.X1VA!E&>\*V:6IXH:;IZZ7
MJ3E^MZ7)[,BJMD+GU929Q@\^&I81:7"?)\FW*09N4Y&6X9]7;\>*S2HTA)BD
MJ(@4P@1H8#!Y^)S?<U%/`]+?W4=<$O%56N9CO,@D`^:4>BGO;ZJM7S"6:C=G
M[/9TI3>"-TE5565'M*L#V")$NIFCRNC\N;FHJN0TK8)M\WC8:#CGLM*R#I0J
M;9C'1[91V\=KJ&\")-VZ1C&'V!K@XXAIM3KA`;2"23L`&))CN6ZWUMVKV;7;
MFU/7"H=0TVVD34MQ:@E"0.E2B`(UH/<EY=K\U^7>3\U-5W!Z2#I*GXN;.$5&
MYVN.JPHNW@US-E2)KMUII=5>15(H4JA#.^@P`)=@TQU7?QJ:_P!3>U?V+T&0
M9B3*)R5U9S-9V3&7HC]=?*5P-:Y>^!=GX?/)2-0^&:JXJ20H+KJ@)4\,P)"@
MT`A@%)RD-!0)G.,O&`.S?^<GM$7_`#+)5Y$W)"Z&'.>(E0!`)1G0JFP6*C3E
M%CI@HDG>8=-T\.W$#'%P5J!1*(F`<\M7#QVNX>OW4IE?7CZRSTI0@=UOL<2"
M5#>2(T7XG<^PTESS6O0%'5*'"B@_W1<QCX:ZVI6)U($R#ZFZ6V@L94Y"]FF`
M(PX]OSE_9.#?*:@9NCB/%J\S>#5LH5Y,HBM.8[FG+="S,2MA.GZDG%^B5\S*
M)B;O&I"&,4IC:C_2VH7M.7IB^L@ED#*\G>IE7I@`8E2",PZPH#$QOKS0\"K3
MS&<&;IP]JBVFZ.-^L6Y\D29KF4E5.LJ$Y-N3+3ID9-.*4`5!,;+7']\J>4J/
M4<D429;6"F7FNQ-JK$VR-UMY.$FV:+^.>)#\@+-ERB(#XE-N`_+K<VCJF*ZF
M164R@NF=0E22-A21,'X8_(QJC3-[T9J*NTGJ1A=+J"VU3M-4-+'>;>:64+2>
MQ0..PX&,,W?ZY6R''?A(^Q]5GCEC=N2TROBUH\:=)5(^CHL0DLD.@4,H42"_
M@C)Q/U2F,`2@F#82`8(WXKWYRTZ:]1IU%%77K\($8$-RS.D$;#D!2D]*@8W]
M]V/P5IN*?,.WJJ[MH<T]I!A-Q4E4Y+JRLMT"92QR/9JG<":<)((.4P8L%8<M
M_(+,&.<*4%D#VV9)M<35(=(ZJ3=!%61=$26>.7*P@BV:1[7K654/]4B:8B.M
M:K=;ZBZ5K-JH0/'?<2A.[+/:>P"9C]'?$C7MAX7:#NW$#4J_#L=IH7:AT@%1
M(;22$I2)E2E*RH2D8DJ$;/SCG@FD<9<)XWP7CUH1K5\=5EC!-5?3*DXE7R9!
M6F)]^!=P-(STLJL[7'?8%%1`OU0``W2L]KI;);&+51IRT[#82.N0Q)ZU&9/6
M8_';Q7XE:BXO\0[MQ'U2X5WBZU:WE"9(;0<&F4="&6PEM'4D$XDQ:AW9\ZL.
M/O`'D1;5WJ;67LM-=8TJJ1PW%_8L@E-7DF9``0'J",<NEA]A$AUC_$&[ILND
M:RJG)U;1;1UK<[@`\YB:^2/AO4\4.9S2MC;;4NAI*]-?4$?,9HOMRK_.);3V
MJ$:V!JR=/UVL<S14</7R[9BT02`157=.52-FR290\3'554*4`]HAK3I;)]4]
M73Z12E"3UF21AM](B/UL/U#-*RNJJ%!+#:"M:C@$I2"5$]$D@X[I&-A9W+>3
MRO"CMFK)_;Q&^7+WC6MX2Q^(F$9!:R3]8;1EGL#<@""R1ZS6"OGA%]A(F\*W
M(;Q4*`[::UOATUHJ6<>T7F4L-[)E:D24J4QZ"0I7:!TQ^6[E%X.IYA>;U+GJ
MQ5H:VW=^[5N$T)89J%.4[)PDKUBH\)HHVJ9\50GD,0GNWWQ4D^:/+/$^"$/?
M48"<F!G,@R[(2>O"8]K9/M6UR)%%3D(DY69I>Z-C"(B+QRD781-MK7#2]@^\
M-[IK*F8869N'\EI`FLX]."1UJ&V/T+<T'&JDY?\`@A>^)+F15SIJ?P:)M<Y.
MUM0?#ID$"9*4K/B.2E)MM9P`,3)^\AW"(?@)QSA\+X<68QV;LH5A:H8[CV?X
MT,98]C6"<&_NYD3',5%Q&MA39PQ%^H%GOXP2*IMU@UL)Q%U<-*VE%LMDA=JA
M.5L;FFP)*<(Z$X)0-ZB!LG'@9R$\KM?S-<5W^(6ODNN\.K/6"JKG%=WVA7+7
MXR*0&0FEQ4W:HHD4M21F0MULQ`?B(F:M4[%P<,U>3-ALDJSBXQDD(K/)69EW
MA&K5`IE#=2SEZ]<`'48?$QMQ'6KJ&E22PP"MU9"4C:5*4<)[9E1,R<9S),?I
MEK:V@LUL=N5<XABU4K"G'%G!#;322I:C+8E"4G8-@PC9<=MGB8GPOX@XKPN]
M1;%N:4:>U9*<M5`6(ZO]F]-_.D*N)2BJE%[ILR>)B]+?ZHB40$=QM%Z?&FM.
M4]L4!ZR$YW3ABXO%71/'#R1^17FUXWN<P/':]<06%+-@4Z*>@2H2*:*GFAG#
M<7.\Z=AFO$`QB\^)9E8)+AQB>MK)$<6RPY[A%*R@FEZK]="+K%B),I-"D`5#
M"<\HT*)`^^,8OS:P7C8\RWING;*<U0JM1D&TS`5.7;,#'#'&-R/=&45Q5QYO
M=W0HIL=+IIT5!G)`4[4,%HJ)(`D&W2"=@!BSKFE=[%VT>SIQVX714A]A9PY$
MP\LOD<K)<RKV$JD\Y5MN4FJ3Q$^R2DC)V%I!@;[U5D9V4OB&X8_J!]_1G#FA
MTJ%9;K6(/BRP(03G?Q'25A$QC(GHB>>7[3UJYN>?/57,!6M>M<.]*OM"A*TR
M0]4LI%-;UE!VAM##M81Z270PI6V1BZ8NQO:\PY'HF*J)'C*7+(MK@J;68\HB
MF5Q,V&10C&15%.DWHMRK.`,HH.Y4TBB8=P#4.4=(_7535!1IS53[B4(`PQ5A
MYAB3U"/9+6.K+)H32=QUKJ-T,6&U43U6^N4\K3#:G%Y1,3.5,DI&)5(8SC9J
M\+>)>/.%7'RD8)QZU(*<&R3D+A8#>H9[<[V_:M1L]J>G5'U"_:3U'9NCX%:M
M")(E`"IZW,TW8*/3=I;M=&)Y1-:MZUGTEGM.P;@`-T?D#Y@N-^J>8/BC<.).
MJ5G-4.%%*QADI*-"E>KTR`,#X:#-:MKCI6X<51W'E#GNG\8<!90SC>)-*,@Z
M#5).32.H4%%7TT=`S:OQ#-O]^Z>2LRLB@FF7<3"?RV#7UOMWI;%:*B[5B@EA
MEHJGTF7=`&\DR`$6'@WPSOO&'B;9^'.G&2]<;G6MMF6`0R#F?=4K8E+;06M2
MC@)1J[9)[9<IY`D9$K165N>2+H[>D8,R"9:1L]SG5'!6;4@B(G4=RDET)@(^
M8A\XZTE\2H>675I*JU]TJRXXN.KGE^LK+AN'5'[(*.GL^B]+M4Q<#-@M%O2C
MQ%[&Z>E9"<RB-R6T3/9@(V2';/X=M.$?$?'6(')&RMY=-C7')\BW`1!]?+&1
M)W*MR*J)IJ':PB7IL4>H`V30W#SUN'H?3B-+:>9MID:P@K>5^4XOO*\@)D!N
M`C\E_-YQY?YA^.-UUTR5ITVA?JMO;5\VC8FEM1`)`4\<SRY?.7+=%_2B2:Z:
MB*Z9%D5DSI*I*E*=-5)0HD.FH0P"0Y#D,("`^`A\VLM(!$B)B-94+<:6'&R4
MN)(((,B"-A!&((.(EL,:PK_*_LS\B?3/^9;^65U>]=`^X>_>Y_9/I^]_>=?Y
M*?6VZ/O/K?-K2*9R>#(^H>V=N[9EZ=GAXR\L?L0_J_KGWAF/X@?<+T9]_)G\
M2>7_`,3A/IPB4-/<?>1BTE(NT>R5V@Y<[N0>+'<O<U4$LBX,LLHJJ\D#+X0`
M#N72@B93ZQC=9AW'S'7H^BNH0D2NMP'\A1_''XNUT3ZC(6^BS?23\D=&<\9^
M1@"<$.PWV@ECG`Q@6)G7&WI$.?<1`Q%,0MU!`#>(](`&ONFOMY]*\7&?[)7R
MQ\C158Q%NHY_3$8.^Z^QR0H[Q=P$3[5O;OXS\BN5=CKQ:->>.UMI%]OT?$M+
M`@S*D>2C:K`IT%I-O/JG>N%B[M$E1`O@)@S33!IOMKPBY5C]$PA0*7`I(V3W
M[9;MP,66Z)<;*:5=%2M/**3-*@?G2`\N\;93[8RX\?>&O,[`V(<=X>/VCNT-
MD9O0Z]&P#B\WO-U6L%YM[END4']BLLS.8PEWSJ6DG)C*J`*JA$]^A,.D`#6+
M7"\VRNJUU/M*XH2LS"4H4$IZA(#S[>DQ>*:@K:9E#0HJ512)$J4F9.\[3YHR
M3\1,`Y:-FJJ.,P]JSMDX6I4)[Y85<IX-M%%NV0:G;(PB:]2>5Z$3Q#`NVS@S
MTHA[VF^25;&*!R;CY8W=ZNE52*%'<*YUU0EE6%)!!VS,_@WQ=[?2OJ?_`*S2
M4R&NE!!,XOF[CW"JH=P3AUF+C):2M6LE;H(\MCFR.D@.>FY4KI%)"C69$_B=
M)-"6(#=X)?K*1[E=(/`^K3I^[O6*[,W!L]Q"I$#YR#@H>3:.N+C=:!NYT*Z5
M8Q(.4[YSF,>O81T1I_L@T*WXJOMTQAD&#=5J]X\M,Y2[A`OB"DZA[)6Y%Q%2
M[!8H@&_HO&QN@P?5.02G#P$!UMO1U+5QID53"@6G$!7D.,0)4L+I7E,N#O!1
M^.)6?PJ/<4'#&?K%P1R1.F0QQR(='LN)COW`E9U_-$:Q`CJ);`<_I-R9`@F@
M)=)0W4>LVX!XF'45<4K!ZY2B]4PFZP._UHGMZ\OP"<9SHFZAE]5O=/V;A&7Z
M0V>?9YHV&7['@._AM]W4"`S$XE.*)\F/YMG(?_07EK_D%/:[MMPN-.?^W1^D
M(ZM=_8GOV2_T3$>?X6.I0EO[2-OJ5NBF<Y4[QG7D#7+!"O2^JTF:[.NAA9J,
M?I`)>ML_8KJI'+N&Y#CK-^(KKC6I$/-$AU#25#J(42)?'%DTZA#MM4TH32K*
MD]<VD"(,/<SX93W`7FOG+C5)HNSP-6LZ\UC67=$`HV+%MI,,S1I8#EW14<!$
M.2-G/0(@F\;JICXE'4XZ6N[=\L;-<D)+N0)5U+3MEVDF?2(BJ^6Y=NKUTRO0
MG@>D;9^:4XE9_"2<_@?0N3.W7D&:`7<*>4S+Q]!XO^,6B7BJ9\H4AB)OK'&/
M?G2FFR)=MB.'IM@`OA&'%:P9'&K^PD9%R0Y+^:H]>T$].6,VT/=0XA5L=/>'
M>3Y,#+R2([#%VG-CU.[3WH\%<!89<\SQ5[?J33D'RJ,U.HI"SV3Q%HO7:3(J
M)'.V769H.F;+I'ZZ9Y!SX;HCM9+1ETOI5V]KPNE:"VT,)I!^</A/U3OB[5^:
M[WA%`V#ZNT>^>KYWE)D@=,USBC?QC)$D^,O#(B*9$4D\[6M-)),A2)I(IT)<
MB:29"@!"$3(4```V``#PU<>$:C[2J29S4TF<]N*L8Z&NP!1-)`DD%0_FRB$)
MQ7_G4\7_`)^1V#/'_K-K(ZF:]'_<]1+9X+GZ)B.+3_;VOPWQNGE=NL=__-_P
M0\_FVUIZ=D;!RF)",-??.YW/>#/!:XNZ"Z6/R&Y!.RX&X]PT=LM.+W2[(FCY
M*R134FZZJM3@W"BZ)B@;:04:DV_&!OEFB[*;U>DA^0HF/M'"=D@00">W;V&+
M)?[AZE0J2W_:7>XGIZSY!LZY1W_M`]ON&[?O`_'6#K#&LGV3[PP5R+R'?N$T
MWIYW)-X8(&G89ZNJGU/6-7C/2ATP.)R*`U.IYJF$>OJJ^N7B\N5R#EI6SE1+
M8$H.!2!O4<<(^EEMWJ5N2RL#Q5`J7UD[L>@2'D,:\+OA]O%SV[.=5YI5<C%F
MN#,O*/LMX(=%1,#!I6YJ05-8:,DI_!BYH4XL9N0GWP,%FQA\_#8#0M_]O69*
MED&L;&1?D&W^4#.<15J>TJMU<2D?9*V'J.SY/Y()]*+N_AJ^Y('#+F*G@3)-
MA&/X_P#*]Y&5-\H_7Z(JG9?3$6]$M(^JJF@S;S:BHQ3Q0?J@59,X[B0-6;B3
MIP7:UFNI\:ZF'1M0=T]_2.R+CHZ[^JU7JCA^R7@>KH/D.WJ/5&S4'V;[[``>
M'EM\@A]T/G'6N<QL&Z);$SCNBV_F2F17A[RR35*!TU.-.="'(/D8IL7V@#`/
MZ6KC:?WO22_IF_\`2".I<?[`_P#L5_HF-+JGX`'3ON!AV#Y@W#[GD&MQDF20
M=\HU]=`+J@=F8Q.%[(W)'NM83[9U8+Q)[>^-^3&%HK(.6)=E<G6?HFG7Z<FE
MK(HK8XUOCM5BO)*GBGA!00,0YC.R%#H+OYP?K2WZ9K-1K5=:UQBJRHS)#9(&
M&&,25INLO#5I3ZG3)<I\RL<XGYMO1&%CN?=]KGISSB++QXR5#0?'#%<7//(:
M_82HC>::SLY-5Z140=5_)MDGCHS3U&)DFP@K&I-V+8RJ8>L13I``S+3>A++9
MRBO;4:BK4G,E9EE"=QP&!(\HBP7K4UPJITJOLFP1,8@CS$YA\71/9>'V2^QA
MQ*[B\)^>/(7,%*[0U`E8U/)?&S'-:E:E?(EVM_E#:(N5CM1&[MG7)@B1BE>Q
M#-=)R0IR).DS@(EM.M-;W6QK-%3TQ2M8.5Q9&4S_`"0-X,MI!COZ=TY15X%0
M7@0`"4@8[<,3@1M$\9'KC8BXZQU1L14.HXOQE5H>D8^HD$PK50J4`U(RB(&#
MC$2H,V#)N3<2E(0NYSG$RBJ@B<YC&,(C`+]34550M^J7G?69J,YDF)0::;:;
M2TR)-I$A&-WO@_V2_.S_`$*N/^4<!K(]&C_S11?M#^B8M]\_=+OT1^D(U'H?
MP9?W&_T`8=;7RFN79\40`?3/X=$;<#L=?V2'`K_0/#?\,36M3M:@#5%<>A_\
M43UI[]S,?1/Z1C&=\6__`&7M;_[R^+__`&2R:R/A=CJ0_L%?I)CH:L_=Z?I*
M_P!&N,ZG`8/^P[P[]O\`)DP@(>?@/YNJ^/LV\]8;?"1>:OH]8<_2,7BU?NUC
M]DGXHP/]_/L0Q7-B!G.6O%.O1\-RVK$0=U=*6Q(A'QO(:!BD!-Z8]()HH91B
MVB0@R<&V"33`&ZHBIZ9AS+0FMW+*ZFW7,J5;#AMGD)V=J?B[,!C^I=.(NC9J
M*4`50_G=<NGX^V-="DI;,?6Q)5%6P4:^4:Q%6071,\K]JI]LKCX#IK(G)Z+^
M&G(63;;E$.DZ2A/IV'(8J:9.8)73+&,N]F21M/2);HB8J>HWRJ4GD'&<]L_)
M,?"#T$1L?.P9WT(;G958CBUR8FXV$Y@TB!*2%GG1T8^-Y!UF'0334GXDIC$0
M2R%'MB=<M')["L`"Z;E],3D2UUUQHMZRU"KE0)"K4XJ8EB$;<"-H3L[,(ES3
MFHFKBSX%0H)J4X=O4>OH/SMV,P*:\,4%#_%0=RQP4HF20XRP153";80]:+XZ
M@G]4?$0$R8AX:[-W5+AQ;DXYO6"?)W_@Z(Z]NF=75).[_%1$LM'[T?W7[!?U
M-1D>N,UCVZI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(^.1CV4M'OXJ2;
M)O(Z39NH]^T6`12=,GJ!VSILJ`"`BFN@H8IMA#P'7%:4K24+$TD2/88[%)55
M%#5-5M(LMU;+B5H4-J5H(4E0ZP0"(BP]IFVONW]W!>3O;3RDNFVBLBVM>]89
ML;LP1[6;E6T<5[$H-FZXB"RMWQ\=NLD!5!])S%*(_6.<-H&T!4*T?K&OT163
M#+[I=84<$DY1)(GO6W(B4\4+&T1[.<[ECI^9[E?T?S<:+25UEJHA1W5A,UJ9
M;4YD=*B-@I*T+2KN]Y%0ESNI3C*IW#4]QXMQ@"^(&YII\?>+1,`51^NVR9R9
M1D:^9=DX336@L912S'\N7S@OUEB?E`@[)%([=`B#E4Y3;I"&HEXMZB-LL8LE
M(HIK[A-,P<4,IEXJND3!R)_.5'IQ[K_E^5Q/XS?Q-O325Z1TBI#V58)#U>XE
M?JB$GT?L%)-0J<Y%"$D26(AY\%^+\WS$Y2XFP)$"JW86B>3>VZ41;&=A"4>#
M#[2M$FJD11+<J<:W,D0>LOXU4H;Z@#3UD7J*]4]C9!2VXN:\/0:3BOS^CY8]
MXN9#C';^`_!F]\2J_*M^CI<M,V5!)>JW?LZ=L$@[7%!1P)RI491LZ*Q5X.G5
MB`IU=CD(ZN5F$C:]#1B*29&S.(BF24>R:$2(0J?0FU1*40Z0WUNFRRW3LHIV
MA)E"0D#H`$@/-'X^+Q>;E?KS4W^ZNJ=NU94./NN$G,IUQ96I1,YS*B3MPC7F
M=Z'ATSX@\TK:SJ<46+Q;F!L;*>/&Z)5"LHU*9=K)6>N-C***B5.$L::Q4B"<
M3`V42$=@,`:U*X@Z>3IW5#K3"<MOJAXS4A@)_K$C<,J\0-LC'ZF/=_<>G^.O
M+[0U%\?\;6=A7[.KB99G"T@>KOJP`F\QD*B`!XB5C&49B?ASN?;F3:S'!3)T
MZ51:%8R%PP"^DW)`56BBN#NKACI%=<Q5%U(M1R$E&H@*A_=3.B%Z4FZ9=2!P
M@U.4E6DJU?=2DKIB?R?\HT.G(>\D?D&6Z-#/>M<L;5$]3\R&CZ<A+[B*6](;
M22`X4A-+7$#!(6$^KOJ(`\3P%$E3JC'V?%'0<RM5.'-D2*L>O1MCS)!OCE*I
MZ",S-1>/W\454P%],JKEC!/!(`CN()'V\AU].-Z%^#;'<?"\5Y/8HMI(\I"3
M\,?'W-EPM[=ZU[:5%(NSM+:GD#":FFG*Y#LAMDE;S4]P*DSW1C;^':Q_$7'N
M$LIZ52:.%,;XHO5PB$7:)EA"5=!&U-)PU#H,D1RT1L2BI#GVZ!+N4>OIUB'"
MBF;J-9!UR14Q2N+$\<24HF.B04>R-L_>HZFK[!RMN6RB*TMW:]T=*Z4D#[-.
M>I4E6_*LL!)`VSD>Z3$^`1*4!$P@4H`)C&$=B@`!XB(CL'@`>8ZVEGA+='YF
M@"2`,3$$_O[=P&/Y*YQC>.^*K*$KA[!#MZC8'\2_2<P5SRLH(H2KMNJU#TG[
M*H-0]P1,*BB?O0N#$V\QU=XHZJ3?KRBTT"PJU4*CF(]%Q_892VAH8;QF/48_
M2/[LOE@JN$G#A[BGK2C\'7>I4(+*'4%+U+;AWFT$*Q0NJ5]LL22?#\(*GLB@
MG9/X-27+KEI6[=985PXPI@61C,@7B07362CYBPL'`NJ33D7(=!'#A[--2.W2
M0"</<VIRG``5+O;>'6FE:CU$AQU$[31*#KBMRG!BVW/82%=]0&R2>F)+]X7S
M'4O`S@C5V*T5"1Q!U(TY14:`05M,+3EJZHIW!#*BVVHR/BN)4DG(8JU\05RW
M)GKE^3"M9>N34/C"P?TA5KN)&3K)LDY3<7V201Z2"`L"MF45XAMU1QS$'I4U
M<N*=^]KZD]GL$^J6]);/0752*S_)`2CR*E&$^Z^X&JX:<"#Q!N[:!J;6#B*P
M*VK3;VTE-$V3,^GF=J<-SZ0H32(OI[*--Q9P;X3YU[G6?`^ST[$E(U*AAZ:9
MIAY2J_*H,`B:T@[!N5:<R-D5(K)`I5`*8C!,QC%3$Y@R/APW0:7TS5Z[N^#;
MDTHP[Q:2J0"1O+KOH_E`)C6[WA>H-:<QO,+IOD_X9_:JI"W4UN)\)-6\VI?B
MU"DSDU0T)\91RS"GUI`*PD'&IW&L79/M6":?S^Y/KS3?/',O,)W^,:"L_<_9
M.)>.,!5YQ]7X`6+ANAU.)7WR,49E(1$I&I#.E0.Y>J].$:KHJ]VWL:LO>87J
M[57V;<R`Q2I;6I*)=)`3V3*L2J-M^5'66D+-Q*KN6'@^FG5PUT#8LEPK0A/B
M7*^O5#27GLR5&26\CZ725*S.%+2"&J=$^_=@'AJ/(?EF&:;3%D>8TXVD:6E4
M'29SM)7(\B"Y*3&?P9VZPQJB"LBHFI]4Q&Q0\S:N/"W3OMG48N-0)T%``K$8
M%Y0[@Z.Z)J\T8W[SOCX.%O!`\/K,\I&K]7%=.,I&9NA04^MN;B/$!2PDI,P7
M"=T3T5W"#1NNZ=KHMFK9)5PX<N%"(H-VZ)#*++++*B5-))$A1,8QA`I2@(CL
M&MI"4@%2B,NW'8/[D?FD::<?<2PPE2GEJ"4I2"5*),@`!B23@`)XQ'Q8U%#N
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MFY:1]A>J)'V$Q%"@8NQ@`0M/"2@15ZL54.8^JTJE@2F,RU!`/:!FEVQ+WO6]
M;UFE^69G3M$M:%W^_4U*[E44DL,H>JUI,MH4MAI*AO22#@2#/#44(FF=18Q4
MDTRF44.<P$3(0@"8QSG-L4I"@&XB.P`'GK9\RVC9'YJTI4M00@$K)D!O..$@
M-L^B(/O?I[EK3D5>PXFX9F4WV&<4V#WO(%HB7Y7,9D7)$:!DB1C)1J<6KJNT
M<YS%`PG4!>1$Y@`H($,?6/BCK)%^K_N];5YK32.`N*29AUY.Q`EM2T<2=A6)
M2,H_17[M'E&>X6::/&W7].6]?7JERT5.XC*Y0T"\2XH*[R7ZL`$B2<C`2DDE
MQ03U#X?'A6PY`\EI;D!>8H)#'W&\(V1AFSE$%&$QE.6]52N)+E.4R2Q*VR04
M?&3,7I%441^0=?+A5IQ%YU`JZ5*<U#0$%(.POJ&'4<B3/M.(V1?O>B<P=5PO
MX2,<,=./^'JG5GB-NJ29+:MS<@^1*1!?64LA0."?$Z9QFT[O/>.L7!6\TG"&
M!:U2KQEN5C"6F]+7`LC)P]0@WZHMZ]#!%04K%R"UEG?3.X`%%2$1:@D8"*"L
M'1(_$/B,]I6J:MMJ0R[7E&=PN3RH0<$@!'>*U'$#HQD9B//'D7Y"K5S(:;N/
M$3B767"W:(9>--1BER-NU3R!F?=\1YIQ`89FEONI)4YG!*0@YJAY(Y_9PP5V
MJ9'D_P`M82I8^Y!Y6K4S#XGH5)92T.X9S]^CY%/'`2D78Y*3?-9B`AQ^V95/
MU-D4&YDA`JP@37<J]772TZ!-_P!1H:8N[Z"&VVYC*IP'PPK,204COK.Q(!C%
M=)\L?#KB/SIM<'^!]177+A=9*MIZY5M6MIU*F:):#7^&XPAM"VGG?ZK3G+WU
MK"\4`JC"U_5A7S^HW_.I]@+?GJ_.A_+!^RO16^W_`,U?Y,?DK]E=&WK>^_D7
M_P#$?H]/7M^*Z?4\-1I]QJS^%GK^0^UO']=E(Y_#R992V^)X7>E^5A'H+_SA
M:;_ZC/W+]:3_``_]B_=?Q9CP?:/C^L>)/9D]:_J.;T?G?JX[O;^/G$1*P2Z#
MCL"=T625))R8&EH3(]V48RYO?ERGE&ZA,^;^D_.'JI[E*/0</JAY:WP:K[ID
M"A=[:.U*?\2/S5+IJ4*E[.K/K'_&BB%RQ%P,I<!/VJZ=B[NVU"KU&,?V"T6)
M[E"\LH:$A(QL=Y)24D_4SF**+!BU(910XB`%*4?'7::J;T^ZEAB[6Y;JC(`)
M2"3T#NB9CXJ10M)+B[?5H0!,DKP`'3,QB'X"8!HO*3DGGGE2CVR>8_*?AV66
ME:EA+&^)\B23^2H,J51FM&M+;DJPV^)LDH^AX$QEC),GIDT';L`$1(``;+[Y
M7.VRWLVLW"FIKI(*65)3)0E+`#IZ_CBS4-,FKJ5O*HWW:<$@!)]$DS`GOD-_
M3U1FP9\7.*94B@Y^'4[F9%4S%$IC9FLCLZ@$^L!SJAG!+8PF\!#;]/6(*N->
MH9?;ENE^S3_BQ>S1TTYFV5<_IGY8SJ=J+`.!Z)"Y,REC/@AR%X+6^<D(^BSM
M3Y"W6S66<M\%#(EE8^=@V4ID"[Q2$2D[DE4063!NN90ABF`2@76"ZFK*U];;
M#M73U+:23F;`$NV0&V,ELU,PUF=:IW:=SH69S^$QF"^7V?W/EWUB^!)`]'\4
M7S"4CLG.-?5\5YV[WF+\Y5;N"8[@"EQUG,8FB9M&,;"5"O9BAV)FU:M$D5(.
MA-MD&M,R-3K#L!I"/#J$3N`WGKA;J'QJ55D?5)]G%N>TH)Q$^A)GV81&.MK0
MI+OM!@=Q8[W498_!WNC!73$2.G7"SX\MU9OU*EG<#<:38(BU56;8JG0>1D]`
MOT9*->H*D$IR&2=(%'<!#<-PU+54PW4LN4CX"FG$Y9'8<(P!A]=.\AU!D0K$
MCX^V-O=VO^<E7[A?"[$/(^&6:IV>6ATZSE6!;J$%2LY2K2*3&W1RJ!0`6Z#Q
MT!7K4-MO=72?B(@.M2=269VPW=ZA6#X6::#N*3L(Z9;#V1/5HKTW*A0^D_:2
MDK'81\NWKG%P7+.22A^*G)N57.4B4?Q[S*\,8^W2'N^/+"H`&#<-]S``;?+O
MKI6M)5<J=/2^W^D([5><E$\3_1J^(Q@@^$_.*G:G:J^&ZG(3-"OM_A9Y,_E\
MOWVLRXF)/M_*/2+"1\)BRZ8.:@,MN9/^C1%O?Q8G`P,M\;*+SCH\-Z]WXV.T
MZGE,[1$3.I/"EPDR),I1V8@"=4E"NCI,Y1V$2-95P<1`J>KIPOOQH;LJT5!E
M3U!!29_/`_PA%KUO:S548K&1]HU('L_OF1[8@B<9>1^2^(V>,8\C\0R*<9D+
M$]F;6:`4<@H>-D/235:R4',MT3D.ZA)V+=+-'2("'J(+'#4XW2WTESH7;?5`
MJI7!WI;01T=DHC&WU3U#5(?IS)Q)'][KC9;_``^G$&U8(XA3G)/-2+AUR7YX
MW63Y(95F95,_VVW@[4Z=R=#K[D[@!713+&R:LD*8"!2_:)4Q`!2#;6S75T17
M7,6^DEZC2(#:`.H8DRW[$^2)FT[2.M49K*B7K3\CY,9>4DE1ZS&,GXQTQ1XU
M<-B;E`PYWMP@3?ZP@6BN`,(!Y[!OK*.$G[QJ/V:?CBPZ\PHV1M.97Z/RQ"!X
MK#_VJ.+F_P`O(_!P!_K-K(!].IGO7[HJ.IA?Z)B.K2/Z^W+I_'&Z@/XJ#Y?)
MXCY>`!ON/EL&WCK3PC,"D8S$;!;H@+<N.;F5^7O>7C^1F'.'F9N=_%WMOV&2
MQSC*DXI9G7J3S-3)-19_D>8F?<W\8N7\JT`=-$N@RB[:*8F'8@CO-EKL]+:M
M)>I552W27.N3-15*>0R$I$CYN':3$>558NOOGCMM%=*Q@)A929'H2A6TXXC&
M0W1E/<=^WN`MCBFY[%O+HBNW4)??EC^`AX#N2MF`-]M8S]R[.3^]J>7\G;U=
M^,@3>JL&89&V>Q[;_F8Q*]WSE-RW[IO'VOX\L79CY88IOV,[6E=L>Y:6CWL_
M^3#8$1;6^'?QK>":N'D-8X0!(J0#_47125`!%/8<JTE06S3MT+HN;#C+@D4S
M3B1L/I'\#%BO[U3=*3(6).`SG)V<L9[6@,#)6)E,1#P.#IFZ,4IW4<_8.^@%
M2^JTD8R3CW(]"@;B1=K(QCU'?Y#IJI[>`AJ9'`AU*D'O3$P!B"D[,=_3+IB,
MDJ<IG0H@I<29RZ>K=@H?`8VIG8*[CK?N#\'JN-QFDGG(3`!([%6:FJRI/M&7
M7C6125/('H[%.9I<X-`JASAU![XDL`COK5W6^GU6&^J\,'U%XE2.@':1Y#\!
M$3AIZZ)N=`F9^W2D3'5L![1L/6#&3;F+_-!Y7A_^M><]P_ZL+3[/;K'+0J=V
MI"-A>;/\],7*X?V%_P#8K_1C2Y%'8/#VF\!^Z/ZFMR6L4IS;,OXHU]=_7*^D
M8V@_PO:":':%Q"=+J`7.4LWN%.HV^RHWZ02W#R$`Z$0\-:Q\22HZM>,L<J,-
MGS?EB9-&F5C01^6K\48%_BINV`7%V18[N-8=@`1H>6)9C5>1\9%MC>[US)BR
M96M9R4LFB3TV\;>$$`8R"@[%"3314-N9R8=9QPNU1XC'W>JU_:(Q;).[>.T;
M)=G1&.ZQL<O]X4R<5'O#KW^?:.L$#THC@=O7G7ECMU<HJ+R3Q6Z<NB0[A.&R
M72`7.E%Y*QH]<I?E%4Y1'J]([D42^\1ZY@$S5ZFF<NWCO(^H]/4M_MBJ)V7B
M8Y#+%*AOF.O=Y(Q&RW9ZUU06@]R>PG#';Y#LZL#NQVY7&WD/B[EA@S&W(;#$
M\A8\<Y1K3&R0+Y(Y!<-?>2=+^&E42B)F4U"/R*-7:)OK)KI&#RV$=4*^@J+9
M6.454G*\VJ1Z^@CMB<:2H;JV$OM$9%#9O!W@]8.$6-=\'^R7YV>T<*.1_2_*
M.`_4U?-&_P#JBB_:']$QU;Y^Z73NRC](1J.P_@R_XL?UC:VQ3Z<^M/Q&-?\`
MYY[1^*-N%V._[)#@7_H'A_\`AF:UJ;K29U/</V\3SIW]S4_T3^D8QF_%O_V7
MM;_[RV+Q_2]SL>LAX78ZC/[%7Z28Z.K/W>GZ2O\`1KC.MP%_F.<._P#NR81_
M_'5?#]?6&WX2O54#M]8<_2,7>V?NQC]FGXHNRW\A^4/$-O/Z?#QU:I3WX1<1
MCOPB)9\01V'VW*6+LG-+A_5FK/DG!,'$MEO&<,V3;(9XAF#<5%IZ&:I%(DGE
M.-02$1\`^V4PZ3#[P4IE92T)KA5J6FTW(_U-6#:CCD).Q7YOQ=FS!]3Z:37M
M&MI`/60.\!\?R]/;&OFK=CNF,;K"6RK2]BH.0\>V5O+0<U&*NH.TTZW5]Z)D
M7"*@>D\CI6+?HB51,X`.X&34*)1,49\=;IZZF6VX$N4RDR.$PN>,T](W8=,1
M<VZ_15&9!RNIPET@$?()=&Z1$3(/AM>3>3>9?=ZY2\CLP%B5LE7CAY&-KH_@
M60Q\;*RE3G\-TPDY[B`F38NYQ"`(Y72)ND5PJ?HV+L&H@XB6NGLVFJ:W4I/J
MZ*K">T$I4HCL`5(>2)`TI7+N5X<JW!WRT9]O<$_Q1/71^]']U^P&H/29I!B2
M<!@-D>W580TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$85.\!VW9GEO3*
M]GK`*KZO<O,#E:RF/92%D"PS^Y0L5)#,EJ_VGZK<S&P0[\QWT*[!0HIN0.@;
M<JX&3C/B+HM>H:5%UM.9&HZ,3:4DY2H`YLF;<H'O(4=AFDC*HQZ#<B7-E0<#
MK_5<-.)R6ZK@9J0J;K6W4>*BE><;\+UCPY*"V'4`,U;64A3>5P8ME*_B[7'=
M@@>5,>7CYR'(GB_F-C\BM=M%6GT`@$\DO((?<7LO763P&WN=G]9$?M&&$`61
M6ZCH@9$0Z/GH/B"SJ!/L:]?U?4S(*5H5W?%RX%20=BORV]J3LFDA1^_.5R2W
M+@Q5'BCPL)O'`6Z%+]/4,GQO4$/=]#3ZDYLU/(_857HK1E2Z0X.]'[[F?&3N
M7<V^7N2<NI\/\SA1HIVIC[%#(L&4Z:&.JF_D&\/(B"KI,0<V=VNO*K?5#H,\
M!,!,5,IABO5]EUMJ/4E1=#;:GU9)\)D88,MDR.W:XJ:SU%(VB/3_`)0^+_*+
MR\<"K3H96N]/G43R!6W)?C8JKJEM"G48)/<ITA%,G'$-9Y!2B(R\=@KMQY#X
MPPF3<_<@:/+T/+5S7-0*I3K1'HMIJN4J,5:R$E-F#K6,@I:9(2)D`HE,"#0=
M_!34@<*=(5MF147F\,J9N+I\-"%`9D-IQG_+./DC1?WFO-?I?C#<;/PQX7W%
MBYZ'MX]=J:JG65-/U;@4VVT,`%"G;FHX$9W1+%,20Q\M3)'DW&)?O$\"Y+G/
MQ<<1&/HJ->9RQA+I7'&"CM1LS6EB"3W2S4S[3<F33:H3\:8%4^L>@7C1$!V`
MPCK`.(VE7-46+)1)2;O3K\1F9E,[%(S;@L?"!UQN[R&<R]+RX<9$5^IWG6^'
M5X8-+<`D*4EHSS4]5X:9E197-*I"?AN.;9"(:U1[9_=(QS;H"ZTCBWG>LW"G
M3;.;KED@XM%N_B9F*<@LS?L':3X2F%-5,//J343$0,!B&$!UX;T9K=AY%0Q;
MZINI:6%(6F04A23@H&>[S*$P<"1'OE?.;ODVU98:G3VHM9::K+!7TZFGZ=YP
ME#C3B2E3:TE&\&6Y23B"%`$9E,]92[K_`"WXL6;C/RA[8UKO3Z4:QSRNY9JB
M*]0L-9NE?,1>!MZ<"L$W&+O!7(9)\FBNU3=-'+A(H)E4#ISZZ5W$*_V%=DO]
MA6\I4BEYM00I"TD%#F14Q,$8@*D02-AC0?AGHWDHX'<9Z3BYP=XP45MIF7%I
M?MM0I-2Q44C^#],7AX+B4@24RI:7"VZVTLE93C9;VWL*]Q[M_P#)N*S4KP3S
MS=:TM!3-*O=6CH`["1DZY,^@LHI$OE3+,S2$9),6[I$BOXI8R70)B@;K#'])
MT&M=)WQ-T]D5;K104.(3(%23+%))E,$`@&0.R-@N;+B#RH<SW!]_AZCB1IFW
MW=-2U5T=0M\+0W4-9@`Z@25D<;6MM13WDA68`D2.5/G9S0[J7(:ARN(N+O`'
MD9A&MV]@XB;7>[/!IK9&=Q#U$Z#Z(KP13K[,JA7:9A*H]]X7<>D82I^D8>L,
MTU3J3B!>Z8VRPVBMHZ5P97'5A!=*2,4H"5%*)C#.22-PC2[ENY?N3#A;J5G7
M/&3B?I345UH'$NTU'3ND4*7$$%#CWBI\2I*3BEK(A&8`JSCNQC,X?_#S<J\Q
M3\?,<D_2X\8T3.FXD6SAS'SV2YI,#]2D?%P+-RNTA5E=PZG+]4.@!$2IJ&#8
M<0TYPDO]P6GVL!;[:-H!"WB.A(Q"9[RJ9GCB8V[X[>]*X+:#M;MOX29M4ZN4
M"$*2E;-`T92"W'E`*=`W(929X`K0#.)G?'/CGB;BIB6L86PO64JS2JNVZ4BB
M)5Y2:DE@*:0L%BD0325EIZ56+UKKG`-QV*4"D*4A=CK+9;=I^WMVJUM^'1MC
M`;R3M4I7SE*.))VQX!<5^*^M^-.N*SB!Q`JU5>H:Q6.U+338GD981,AIEL&2
M$#K*BI14HPVN[1VC.6$;RSRGFG"6,K5FS&>;[C+9$1=TB/\`M::J5CMDFL_G
M:S.PJ"AGR2#>6<F,T=E(9!9NH0#&*<IRAKOK[0FH&M05%RMM,Y5T-6LN`MR*
MFU':A229RGBE0PEAMG'OCR0\\G!&KX(670'$2\46GM7:<H&J%2*M?A,U+%*V
M$,U#+I`05*;2/$;)"TN)40"@I)O?[=G;?YGYVJ7'N`Y]F=4WB7Q>FG,]B[C+
M/1C5A.Y`L1G$A*1<I?H]J!A/7X=[**`4L@85UD#G032*1590<@TAHK4MU:HV
MM7?9:<MZIL4B@,RU`32IV1,P@D@`^;?&NW-5S8<`>&M\U3<^6;)<.-^L:=+-
MQO[+BELT3`"&W&Z-:MC[J6TDE@!"%A+BEJ4AM`R+=ZOM]7[G!QSJ"&%2QRF3
M<*6)S:*W3W2J,:TMT"]B%(J9K,6Z4%)G'RY$B(+M`4$J*@MQ1W*)RB&9<3=)
M5VIK.RNTA)N-(X7$H)`#B2@I4@'8%2,TG9,2,:I>[XYH-,\NW%:N<X@ET:0U
M!2IIWZI(*U4SR70XU4.)$UK:F5H<RS4G.')$)4(P==LJ\=SOMV+9!Q=#]N[)
MN5(;(\Y&33V,E8J9J$G$3D8S7C2.FUF3CI.(6BW"!]CE7`"$$O650`W`8QT9
M6ZZT>X[0,61^H9?6%$$A!2H"4PK%)3+ID1'HSS?Z=Y/>:ENUZRK^*EGLM?::
M=QI#C;C-2VZTXH.%*J<K;=#@4#E*"29Y2@X2SJA@/G7SXC$V'-"2A.)W'1^=
M)>6XVX,M+R:RKD=LF1(WV/E#+R0-6D+47_68',9%H`X<E*9)<Y"FV"3O8^K-
M7-^'JA2+=9"9FEIUE3S@W)>?$@E!^<AL3(F"J4>;IXF<M_+-6*J.`#-1K;BL
MV"EJ_7>G0U;J%1G]K;[8<RG:E$NY45"RA!(6V"I..66BT.FXQJ%?H./:Q#4Z
MF56-;0]?K=?8-XV*BX]HF":2#9JW(1,!';J.<=SJG$3G$QC"(R'24E-0TZ*2
MD;2U2MI"4I2`$@#8`!@(TCU)J6_ZQOM5J?5-945]_K75.OOO+4XXXM1F2I2B
M3U`8!(`2D```6N\\>$V.>>>`9G"E_=.8)X1^A9J+=(YNDXDZ9<H]LZ;,)9)!
M42`^CG"#Q5!ZT$Y"N6Z@AU%.4ARV+5>F:/5=I5;*HE"\V9MP`$MK&Q0GM!Q"
MA\Y)(B9.6KF&U9RT\3:?B'IA*:E@M*IZRD6HI;JJ5:DJ6T5">18*4K:<D2A:
M1@4E2514^/O%3N6=G/E!-Y4J7&M]R4H,C7Y^A3C_`!ZJZDH.W4IW)1DNVE4Q
MC$7L[4IEN\AF[A%-XS-L)%$3`('Z]01;;)KGAW>E5U-0&OI"DMJ+2L%H)GFE
MM0L2!`(,\1'M/Q0XT\HW/IP<I]&7S5C>DM3-53-8TBM"6WJ:J2AQI39\0H9J
M6BAU;:BTZ)S2L$%,HR7V>T]VSN@M1Q0TPZ?M]<9;&3W'(U[L[Q\ZRE8X`P>L
MYCX!%8(66!"52(9L=%LV224ZP!5T5/K`<OJ'N(NO![/%,;+8%B3KBE3?6G>E
M$I2!Q!D,?R@)QJ#9[+R0<G;WWU?OPXH<7:0YZ&CITH3;V'@9)6^1XK4VS)P+
M<<6H`?9LE>4CJ7<-['S!'A7A_'7"NJIS]]P79)B?GFTL:);7?,#>W,VK:RR;
MJ=6*S26EX]VQ069L!4*W3:E.BB'J#NI\]6\,`SIFDH]*-A550N%122`MX+24
MK)5@,P])(V82'3%]Y6/>*5+G,%?=5<P=::;3.HZ1IEE3?B*I+8:92E,-I9&<
MAIQ"UI=>`*U.%*W#E]&S7M@1'>"X?5C+&%<2\(EW:61YY*4:6[-!%Z5"T*WM
MHTL2,NN[<O&[6Q1!6J29C-0,4!.3<J@@;I''=&)XD:>:J+=;+3F2^YFSOJ\-
M+:Y2*L"<Z=\L#VQ/G.'7<B7'>[V3B#K?B(E"K33%M5-:R*IZMI5.>+X00E"E
M,.9BH!R1D#B@2G%_F-NW3@?@[*6?N*]T3.T3F',Y)5S;G+B6:^\T>,N4B45&
M36M5UX@>5OMN:GV1BD$T$6S02%]%OL0BA,HH=&6G2CCFM==UB:JZ9BLE0DV%
MG8$(VK6/10/F_-`VQK+JWFLXE\Q=%1\JW)SIMZPZ`+":9(:5EJUTJ#):GWTD
M-T5,H354+*U+<!/B.S4I*K;,-X_S)WW>64=R,SK6IW'_``'P5+/$L4TA8ADV
M]]?-)2-74@EW"I@2E9*PD;$6L4@@0R+9LFG'H&$=U=66V4MQXLZ@3>[HVMG1
M]&K[%&SQ53Q&WO3D"XH"0$FP?2G+6O=4:"]VSP2=X5<-ZNFN?,SJ1A!N56#,
MT:%-K`>"1BVVP5*10LK(6XXI54Z)=R):'N++W#[,]R;?9ONON'V?[NE[E[AZ
M/N_N?NO3Z'NWN_XOT^GHZ?#;;6P>5&3++N2V2PV;)='5'B)ZR_ZQZYXB_6\^
M?/F.?/.>;-.>:>.:<YXSG%`N1O*GCQQ$H*64N3.8*=A?'Z\RUKK6SW:248,7
MT^^0<NF<-'IHI.';^2<-F2RA444SG$B1C;;%$0[M!05UT<]6H6RZ^!,Y1+XY
M1T*FI8I$!Q]65)V"1)V3V`$_!$%GOQ_$44/EGCF;X:<()Z5##UD<`VS5FYZ9
M6O+9#AV2Y5"T.CQJRB,FG49-TB4\B]<%2,\1*")$P(8XFFC0^@%T-0F[WHH#
MZ<4(G,`C>K=YMG;&`ZCO[SS1HJ%MTIWDI/>^#`#H.W#"49/_`(?_`+L';'PW
MV\,2<>;MR$QM@++N.U+.MDFO9(E$ZNG9+'-V&0D3V^&F5B?94NR?QAVR9A]8
M%DA2Z#$V*`CC.O-.W^IOKMQ:8+M*L"11W@``-PF1L/5%XTU7TC5L0P\5MO9C
MM21,D]8Q.SKB6+5K77KO6X*XTZ>C;-5+/%,INNV.#?)R$/-P\D@1RPDXU\W.
M=!TT=H*`=,Y1$IBCN&HU6DMJ+3J<CJ3B-X\\9:E2%C.@S2=D?NB(B/WPC[=_
M']4?DW$=<)8Q6/SY65C(**DYR:?M(J&A8][+R\I(+IM6$;%QS95Y(2#YRJ8J
M3=HS:(G45.80*0A1$?`-42DK6&=H5L`VSW;(XJ4$@J."0-O1$8OO:=U[M59)
M[=7);!J')K%&;;]DVC.83&M&QA-L[G,%R(W<H25-LJKQD52,A8^M6!D@\6=*
M+%$J28@0#B;89"T?IS4#=[8K"TZU3!0S*49301B-Q,_+TQC5]KZ1VW.TZ"IQ
M[*)`(*I$'`G"0^.-:^$BQV#JD6/5_?;.V^PCX=0_PGD(AX:V4\1!P6I)\OPB
M(<-'5S,FG)3_`"5?)$@3L*=YBM]L'+MVIN:%)2:XO9O/%*W#\G54)*5QQ=8H
M#-XW($;"BL0\FQ7CU3-9)!(Q53)@10H',F!1CS7VDQJ*E%30E/K[`D`2`5B>
M*9_#.,OTK=*BV/>!4-.^K+P]%6[9NVC9V;-D2QNY5WX.VC+]O+D`WPQRLQ]E
M#(V7\46?'./Z%4%WJMP6F[O$*PYU)J)>M&B]?8Q+9ZH=TLYZ"EZ=B=8B&HMT
MYH^_>WZ=513E%,VX"I2E"4AUSQV;HS>[7:E5;GD,E2GB@C+D5F$]LQ+#`[XQ
ML?#'=UKA!Q_X>V;BCR'SA2,'9%JF4K9>(61R).-H2K7>M7(S5^1>%G51]P0D
MX=Z19!TU6.0X%*14G44X@7(.(^FKG67-%QH$%^G+8!R'%)$YX;91;=,7-I-*
M6:D+:.899I./=`E.6V8)'5$R2PP6)>46#IRN/'$#DK"N=\<2,0L^C'C:7K]O
MH5Z@E6HOXI^CZS9TTD(V0]5NN01`!$IR#OL.HH;=J;;6)?3F14LK!D=H(^'^
MY&7N(9K:939DIA:2#YHUH7$+LV7JS=ZJ1[?618U[(4'CSD9W?\KSZB"I6DYQ
M_K+ME8ZA+BH!!!(N5(E_%QZ(_P!XX?JE_P!A/ML5=M8L-:0%X94DU%0U(`$3
M#JAB9=`WQ$M%IYU>H/5'00RE9),L"$[0#*4Y$?6$;/::FZGCVIR,].R$)3Z1
M2X-5[)RDBLWB:_6JY",A,JY<N%!2:1T9&,&_B8>DB:1/D#6MZ/$?<`2"M]PX
MRVDGXXE\EME$R<J`/,-D0._BJ^>7#[D[COB?CGCSR`QSF:U4[(%RN-K1Q[.M
M;%&0%?>5E.*8KR$TS.,>F\?/E=DD"G,H)"F,(``!O-?"ZSW&W53[]:PI#90,
MI7AYNF(^UE4-53+;-,5+6DF<@=IE@<-N$1'\!W>KT//&"KW991!G6J1F?%=Q
MLCQ(R;I9G7ZU>H*9FGJ35-3U'*C2-9JJ`F3ZQ^G8/$=2Q=6EU%NJ&6)*=<0H
M`3`EW9>:,$MK;K5<VIUMP-A7Y*O-LWQ/Q[P_Q(G%:D<:K)BG@?F>`S%GO,U5
M5@FEXIRK@*WARK6)D=O,6-_+/$&@'O/V6N9*/9(@91JX4!94Q!1Z#0-I/0-R
MJ+FE^[H+%"TJ<E$=\@S`[)_!TQ)U^U`TW0J:H,ZW7!*:4J[HWB<MN[#9YHJ5
M\/#SB[:&/^`.`,`5+/V+J#R"D7[@<PT6[S["LWVXYUM\UZ4E)-_M-1(;4G..
M56[:*.@HJ)FQ$D@*4Q>G77UY9[^N^/US[3BJ$>@I.*4H`V8;);Y]N^.SI^NH
M4424$J0^I1)"P02=@ETB0`'9(XB)1XF4`?$QO;YCMY_+X^'CJ.A*,G&R>^*,
M9LY&X)XU5N.N/(',./\`#=6EY4D'%3V1K3&U>+DI@[95X2,9.I5=%)R^,U;G
M4](@B?H(([;`.NS34=97++-&VIQR6(2"2!TX=>$?)UYID3=4$C\/Q8QJJ>]V
MZX8K=QC,]KX39,I%^Q%D5"&OT\YI#M$]/@LISY7*E\AJZ\`$FSQFY?)$?*&0
M`44W#I0I1';6SNAG+JW8D-WA)15(.7OG'+NGY(AO4U*TY<"Y0(<6T3.80J6.
MV1EL!F/++8!'YW9Q[EA^V=S/J68Y23</L*W)H&/L_P!:B7*3IS(T1^X!9G8V
M$=[PF1Y.4>5$KQN41`RB/K)%'<X::QT^SJ2V*904"J226S,>ET'J.S^]'+3=
M;66NK'B-.EE9D1E5OV[O*.L2^<8V"'+#O&]L.>X2\@)ZO<T\&SXWOCYD^%JE
M<B+@R=W29G;;0YJ'@X1&HEVG4)5U)R*2(I+(I^B81ZQ*4!$(&M>F+^S=V$.4
MJTE%0B:I=P!*@29[);]IB2JVZ4:J)W*O.ZIM8"<IS3*?1E*?GV1JF$Y&/$H"
M9^R*`^/2+MON`#X[;>I\FX:VG2I``:!2%2Z=DOP,0JY2U2G20T[Z4_15T]D;
M$OX;WN/<$\<=N#&F`<B\FL1XTS#3LBY';SU'OEKC:I+.U+C=GTS6W\,,HLBW
MFV<JPDT2%.@<QBK$,F<I1`!-KUQ"L=V=U$[64[3CU*I*9+`S#`#`RV2/3$K:
M6K*=BU)IJA2FW@HF2@1.9ZQU>2)/>>L'XXY*X9R3@;+D"VLV.,JU*5J-HBW!
M"'`["5;&33>M#F`1;R$<N)'+58NQDETR'*("&HYH:QZWUJ*NF5EJFU!6'5CY
MMQ$994LMU5.IE>Q0E_=[0<1&H)[@'#:^=OCE?E/B[DM111>E2IGE%M3H`:M[
M_C*7.JXIMQ8F4Z"+'>1P`@\`FX(OD%2#Y!K;+3U[IK[:6J]HCQ%)[P)V*&!3
MY\9]G3$&7FT5-!7+;2A2F\VY),CMW#`$8I\J1/*8S0_#N=Z>K\`K].<:.3%T
M"-XEY7DSS<):'*IY!GA+)SCTTG$NJV;BNY2I-O3*4LCZ)#>ZNDR+](@)P'#.
M(.CC>V1<[;E-T;&*<.\GHZST>;HC)]*WAZC/JM8ASP%?FJ^MLW2D9;1([C$E
M[O-=U'MVWGME<J\=4'E]A"_7W*>,T:U0Z?2;C'V2P3\O)V"%6011CX\RAVJ"
M39NHJLHOZ14DTQ$?K;%&--':<O;&I:5Q^G<0PA9)*\!L(..&^,LO-QHW+6ZV
MA9<6H"02"3*8/1NWQK,??F/2!??F93`4`$/>F^VXB`;[@IY!X?I:V8"VP!CA
M+''&6S;VSB&A2U)5BVY*8QRJZ.R-EQV6N[GVZ:SVU>+.+,D<L,,XLR;A_&B5
M&OM'O=I;5J6BI."EI1))VB61*BA),Y1D*3I-5N=0!]40'8Q1#6M>L-,7Q6H*
MEYEAQUAY<TJ1WAL'EGTSB8[#<J-BU,T[RBAU"924D@[3CLQ!C$Y\3EW<>&7*
M7CKC7B9Q=RW5LWSSG*$7DZ^W2GO#N*A3XFI1\FUBX0DNN1NC)V">E)$HB1`#
MIH-43&,;J.4H93PWTO=+=<7+K<4EEI+>4!1&91)&P>3?UQ:M3W5I^E0S2A;O
M>,R$*EBDIPPW3)Z,);XST=JSN_=O/+O$OBGC1IR9QG2LNP&,L;X@E<27ZRL*
MY>2WFLP455#1T>P?'13F$IE^S`[!1J=0%TU2AX'ZBA@^J=,7JDNU34.,+-(I
MU2TK3B-I.,L-FV,@M%SHUT#36**A*0)*!&P2Z,0>G9&>40V$0]@[:PV+V"2,
M8?)OY"&P[[^/@(;;?HVUPRB9F<#U;.OMBHP4)8=/7U1#B^(0["2>9V=OYT\*
M::F3,D>W<S^><+UQHF@GE:-:HG7D;_2XY$I"%R(P1(*CYFF`?;"11,4/>0_'
M2[H+7:[>M%GNR\U(<&UG<3AE5^;MET=D8'JC3#=6E5=1C*Z)DI_'\OGC&Q\(
M`FH3GKR1(JFJF=+BK)HK)+)'15072ROC]-9NX2.4JB"Z2I!*<A@`Q3%$!#<!
MUDO%A;:[.P6R2#4!4SOFD_!AA%HT,A:+@XA8DL-D$>5'QQL34/O!_=?+]P-:
M_IG+'K^.)3CW:K"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0@/D.D(PU
M=QOM!8QYCN39FQ-)IX,Y8P;IA+0>48/WMC'VA]%&1,S2N;>)40=%DVY6Y/=)
M=L)7K8Y"]?JD^J$::UX<4&I5>T[<H4FHT%)2\D&2BG9G`D21L"A)0ZQ&_'*A
MSU:OX"-C06MF3J/@E4)6V];WLJUTZ'00LTJG`4ELYCXE*Y-IP$RR*Q./S#O=
MHY7<`;DQXY]V+&-JD&?JIMJAR&K+)O)J2D.@=9F:2D5V`)1=\9F6;=?O+84)
M-,I]UT#?5WP^V\1-0:.J4V/B*PX1.3=4@`A29RFJ4@OIF)*Z4QL_K[DBX)\S
M=@<XK<DUYHFJC*555DJ%*;#;IDH(;2N;E$N2I9'`NG41)MT8Q(TPCR!POR/I
MD?D'"&1ZOD:JR"0*E?5Z22<.&9O443,VEXM3TY6%>IJ)F**+I%%3PW`!*(",
MTVN\6V]4J:ZU/-OTJA,%)GYQM!ZB`8\I.(?"_B!PGU`[I?B)::RU7II4BA]L
MI2O`$*:<$VW4$$$*;6I.Z<P1%8]P]NKE.,#AY^0_H^?2$``?T?M:0@/B&D(>
M.AZH2@.J8P@`;#^C_P`NJ_'#JW1SI".!W^32$``?`1\]M(0']'Z/;I".``?T
M?+^P&F,(Y`-OT>7]S3XH1SI"&D(X'Y/';2$<!L'R^SS_`+NG5"/4Y70;(+.G
M*R3=LV14<.'"ZI$4$$$2"HJLNJH8J:22291,8QA`I0#<1VU0E(!*I9=\<VVG
M7W$LL)4IY:@E*4@E2B<``!B23@`,2=D83.97?&XU<?I%[BW!:+SE'R`<+N8*
M&I^./7DZHPLX^JV:,IJRL$G`2RA7O1U-8DKM50@B4%"&WVBS4_%>P65TVZUS
MN%[)RI::[P"]DE*&&W<F9VXB/0O@)[NGBYQ/I&]8\2%(T;PR0E+SM572;J5T
MXDI:FJ=93X0R3DY4EM*3(E*A%F^&.V?S`[B62:_R4[KML?0]`CQ6?T7BQ!.E
MH8C%N?TP8I2K",<'9U*-6*!S.4_47EW@"`*K)%,)`QJUZ%U+K6N;OW$=S+2)
M!+=&C!(G^5(D)PP.U9WD1/FON;O@5RKZ1JN$G)51-/ZG=DBLU$\D.YR)YRVM
MQ(74N#`(5)%*T9Y&UD!427*;3:KCRJP-'H]>B:I4*M&-8:O5R"9HQ\3$1C,@
M)MVC-H@4J::90\1'Q,<XB8PB81$9RIJ:GHV$4E*A+=,VD)2E(`2`-@`$>1E_
MO]ZU3>JK4>HZI^MOM:\IU]]Y16XZXLS4I:C,DGS``````1V;7WBT11W,_'S!
M_(NKLJ3GC$]#R_4(Z::V-A6\A5N,M$.RGF2#ELTF&K&50<((R+=N]6(14H`<
M"*F`!V,(#]Z2KJZ%TOT;BVWB,2DD1\7J=BH3D?0%)'3YOBBW-#M?]NMJ42-^
M$_&A(AC=0E+B.G@`CMMOL,8/CL&KD=0WTB7K=1]=4=;V7;=H8;G]$1YJ]L+M
MVKE`JW"?C,L7Q^JKB"F*%\?`?`\4(>(:X"_7L>C5O_75\L!:[>,4LM@]@B\N
MM5:NTV`AJI5(2,KE9KT<TB(&`AFB,?$0\4Q2*@SCHU@V(FW:-&J)`*1,A2E*
M4-@#5K6M;BU.+)4XHS).)/E,=U"4H2$I`"1L`C]WTR?@AKC'*/SY6'BYN,DH
M:78-9.(F&#N+E8QZBFY8R,:_;J-'S!XV5`R3AH\:K'343,`E.0P@(;#JJ5%)
M"DF2@00=XE%"`H%*L4D19NCVV>W\W`"H<,>-2!0`"@".(*4F'2&P`'U(@O@&
MVKK[>O4@/6G\H'Y:L/ACI&V4"O29;/:(^C^KBX#?T.>./^J2F?YIT]O7K_:J
MCZZOECC[*MO]`U]40_JXN`W]#GCC_JDIG^:=4]NWK_:G_KJ^6'LJV_T#7U1'
MK#MN\`@$3APUXW%.;[XP8BI8&']T8(C<0U7V]>IS]:?G]-7RQR]F6Z4BRW+Z
M(CA7MN<`5R"FMPTXV*ICYD5Q#2E"#N&P[E-$"'B&@OUZ'_>G\?SU?+`6RW@2
M#+8\@B[:KU.M4FN0=0J$#%5FK5F+8PE=KL&S0C8:$AHUNFU8147'M$TFS)@S
M;I%(FDF4I"%*````&K6M:W'5/.$J>69DDS),=P(2E(0D`)&R0C\5AC#'D9?Y
M_*L=2:RQR5:J_#56RWQK#LD+9/5NO+NG4'!2TXFD$@^BXIP]5.@BH<Q$S''8
M/+55.O*833*4HTZ22!,R$]I`Z8XAIL.%T`>(1(G>?PPC]VS56MW.NS=2MD'&
M6.L66+>PE@@)AHB_B9J'D4#M7\9),7!3MW;)XV4,11,X"4Q1$!#;5$+4VH+0
M2%@S!&T1R4E*TE"Q-)&(BQ]OVJ.VPU3*BVX-<84$B@!2II8?IR90*4-BATEC
M=M@`-7C[QWX;*RH^NKY8Z7LNW?T#?F!CW_U6/;@_H0<9?]4=0_8C=!J._#$5
ME1]=7RP]EV[^@:^J(\"]J_MO%#8O!WC&7Q$=BXAIX!N/B([!&@&XCI]Y-02E
MZY42^FKY8J;7;C_D6_JB/TX/MC]O.M3\%:J_PNXW0]EK$M'3U=G8_%%2;2D+
M-1#M-]%RD:]3C07:/F#Q$BJ2A!`Q%"@8!W#7!R_WMY!:=JGU-D2(*R00=H@F
MVV]!FAEL'J$HOC](N^XAOO\`*(_KZM&'ECO?%%)\NX#PGGZ$CJUF_%-!RS7H
MB4+-Q<+D*KQ-KBXZ7*BLW+)LV4PV=H-WI4'!R`H4H&Z3"&^PZ[%-5U5&OQ*1
MQ;:^E)(/G$?)UAE\97DA0!WQ08G;?X")E`J?#;C<0H!X$+B.EE*&_GL`1.VN
M^;]>CMJG_KJ^6.J;7;CM9;^J(\_ZN+@.'EPYXXA\GAB2F^7R_P#ND-<?;MZ&
M`JG_`*ZOEA[*MHV,-_5$?.';8[?Q5!5+PQXTE6$1-ZH8?I('W,.XB)PB.K<?
ME\=5%_O:?1JW_KJ^6.7LV@E(LMR[!'O_`*N'@-_0YXX[_P"B2F_YJU3V[>?]
MJ?\`KJ^6.(M=N&QAKZH@GVX^`Z+IJ^2X<<<"/&+A)TR=%Q'2P<-7+=0JZ"Z"
MWV2)TE4EB`8HEV$#``AJOMZ]%.0U3^7Z9E\<<DVV@204LMB70!%YX)$``#I`
M`#P#YB@'2`!]P`U:)`*S#:3'<D)2W1;?FGAQQ4Y'3<-9<]\>,19>L-?C5H>$
MF\@T>!LTI%Q3AP#M6.9OI-FNX19'<AU^F!ND#>(!YZ[]'<[C;VO!HGW6FB9R
M2H@?!'7?HZ6H5G?;0I76(HV/:Q[<`[@/"#C*(#X?_:.H#X;?+_N;\NNY]XK]
M_ME1]=7RQ\?9=MG^H;^J(]K3M;]N-@!@9<(.,38#")C>EAZEDW,;;<=PBM_'
M;QUQ^\-]WU=1/Z:OEA[+MW]"WYA'V_U9';R_H5\:M_'_`*(Z</\`Q7JGM^]G
M`U;_`-=7RQ4VNV_T#<OHB/4IVP>W6K_"\)>,J@[;;J8?IAQ#Y-@$T2(@&VJ>
MW[Y.8JG_`*ZOEA[,M\L&6_,(\R]L7MWD`"DX4\:2%`=P*7$5-`/'Y@B]M4%^
MO8V53_UU?+`VRW':RV?Y(C]F![<_`RK3458ZWP^XZPL_!R+*8AIF.Q13VTE%
M2L<L5PPD6#Q.+*NU>,UR@=-0ABF(8-P'?7%=[O#K9:<J7E-G:"LD'X8Y(M]$
MTH+;:0E0Z`(O-],H[B)0$1'5LCN0],GX(:0CQ](N^X!M\X"("'W/G_:U24!@
M9Q99AGMX<1N/G);,?+?#F)H^A9MSU#'@\G3D')RS>#G6CB5BYQ^NA4??!K43
M(2DS#HNG2[5LDHNMUF,(B<V]WJKY=*ZWM6VK=*Z1DS2"!/`$":MIP)&,=%BW
M4E-4&I83E=5.>)EB03(;!,@&+UR@!0V#5I``$A'>CG2$-(0TA#2$-(0TA#2$
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MJK;9:]9('SW6'067%2&UI5.HJ)423MI@T[F?=>X)F3K7.CB`\S31X$YF"F9,
M?-EVRLC'1I0;A,.+15V<U53)KHD!7KDF$<Z6-N*G281VZ:=<\0=)J\#5EL55
M4B,/'9GW@!Z4T!0,]O>0CK/3E[_*'R4<R(5=N7'73>G]1U("A:ZU04$+<[WA
MIIZE353W2<I##S[:,`F8`GD3X\=\_M[YX:,D9/**V$[4Y5!L>L9=CEH1+U]@
M$QVUJCPDZH=GX^"CAVU./RIAK,K+Q6T;>6P55'JK^PI>[LC],31YU`]4:K\4
M_=Q<T/#5]QRBLZ=0V5`S"HMC@>,NA5.OPZD+Z4H;<`W*,95Z9D2@9'C"S6/;
MS3[W#G*4Q96FV6&L\:)3[]`@]A'KUML;8=OK>.VI`IZNEJT>)2.MNM]*%!0\
MX)C2W4&EM3Z3K#;]4VZOMM>"9MU5.[3N8;>XZA"O@CN&X>W78BPPW#RW^;28
M.R$-PTV0CG?2$-_DTF(0TA#2$-(1QN'MTA#<-(0W#2$>"JR2"2BZZJ:**1#*
MJK*G*FDDF0HF.HHH<2E(0A0W$1$``-4)`$SL$<T(6XL-M@J<)D`!,DG8`!M,
M65YJ[C/![C^DX_.?R7Q;&2#;URJ0,%8$KK9"N$"F'W5:`II)Z39N%#%Z2@X3
M1+U"&X@'CK&KGK'3%H!]>K:=*Q/NA06K#;W49CYP(V!X?\J/,5Q/6@Z/TA>7
MJ54I//,&D8(/SDO519;6D#$^&I1EL!,8?[K\0#.97GGE!X`\/LIY[M!W/N+"
MS66+D48%)<3J)IN7E;JA7[M!BJ0OJD5>2C`"D_A"E\=HVJ>,*[BX:/1MMJ:Z
MH)D%$$([>[.0^DM)\\;UZ>]V';M$VQO4W,]KNSZ9LH1G73T[C9>*1(E**BI*
M$*6#W2EJG>)5Z).$^E-NWIW6.XB\;6OG;R3=<=<6R2Y'(8&QJN`R+1BENBFW
M7A81Z2JQ[Y9$XCZ[UU++&`/QA`$=@ZOW-X@ZU/CZOKS0VY7_`'9C;+H,CE$Q
M/:5GKC(7>:3DLY5V%V3EMTDC56LF4E/MFO3W%+.)4'G4FH6@'YC+=*D'T5$"
M9S+\/^VOQ+X2Q""6'\;Q[BXBD0DID^WIM[%D"4.4P'$WVTZ0`(E#U=S%08D;
MI%W\"ZDS3>B-.Z5:RVNG2*@^DZOO.D])4=G8)"-!>.W-MQOYA:Y2]=79U%A"
MB6[?2E3%$V#A^J2K[54L"MXK4>F+]0#;66QK3'.D(:0AI"&D(:0AI"&D(:0A
MI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D
M(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0A
MI"&D(:0AI"&D(:0CYUFZ3E(R#A%)=!0HE4163(JDH`AL('34`Q#%$/,!#5"`
M1(XB.;;KC2PXTI271L*201Y1C&/SD)VKN"')MVZE\G<?JFG9W:9"*V^E"]H5
MF.9(3&35<253<Q0R!TQ./\9*L40\!`0`-8?>=`Z2ORB[<*)HU!$LZ)MK[<R"
M#\)C:#A=SG\RG"!E%%I#5%:;0V2135>2M8$Y3"45*7,@,O\`)E)&T&<8K+S\
M.33ZR^=6?B?RTS5A>S-S'=P;6=<HSD:S=$,"K5LC,5E2H6!FU35*'XPYW:H;
M?*.L"J>#%-3++^G+C5TCPQ`)S">Z:AE7+I[QC='3GO6[[>*=%HXVZ(T_J"T*
M`2\IE)9<6DX*):J!5,*409%(#23U".L+\??B+>.Y%!QYR0Q]R3AFO2=./GIR
MMSL](I%\TUE,OU:(=(*])`W].8ZA$1V,(^.OF;3QFLP_J=;3UZ/SRD'_`.HB
M?;]IYXO#?%#W5/%0@:JTG<])7!>U;+-0RRV>H6NH=21,X3I92V@1\8=R+OFX
M>3]#+_;A;WYLR_CDK2Z#=Y1XJF`;"/O^-+;<X``$?'<C78/9KC]].*=O&2X6
M/Q2-JDI,CY6W'?)W1Y(^YY3/=R:\7XFA.+"[8ZYZ+=76TC:0?H5]-2/;-Q<G
M'Z[;XCX]$%O&<B>">9L7S8>#HI)I9H"@@<2G.VB;O3ZD\3`OX)ES^/RZ^B.,
M_JTD7>T5K+N_</,ZEHR\\=)WW3R-2YZOA5Q)L%XMVU)+05+M=I*JI2>W(GLB
MJ\#\2WP3D"E"<QYR/KZP[`8`J%#EVQ1';?\`&M<D)+"`?XK]+5P:XV:16/M4
M52%'=E0KXG(PFZ>Z+YD:4SMMTTG5(_\`%5K2O,J@(_G>6*WP?Q!7;1ET2JO<
MCY!KBA@`PMIO%%M57((_WAC0#:=;=1?F4$/8.KJSQ<T4Z)E]Y':RY_@A0^&(
M[N'NO>;JB<**:TVNK2/G,W*F`/\`GU,J_FQVC^OJ[8/G^?J;#Y=OS1Y9^7;_
M`.CMOEUVQQ0T41_:S_FG?\2+-_TT><6<ONS3_P#$[9_^5'R.N_GVQ&Q#*)YL
MLST2E$P)M<29/`YQ_!+[W6&I`-]TP!\^OF[Q5T2UMJEGL9=/^!'W9]V7SAO*
M"5Z=HVP=ZKE;Y#ZM0H^8&*03_P`1_P!O.'.JG',<_6@2`/0K#8X@FK=40W``
M`UBO,(N0#;>8IAM[-6IWC-HMI4@:E7_RP!_/6GXHSJV>Z=YI:]*35N:8HI[0
M[7/*4!U^!1O)/UHHC-_$V\<3J^ZT+C;G6VO5!Z&C64?TVOJ.5!'8A`)%R%P6
M`3C[$SC\VK8YQOLBC*AHJM\]1;'Q*4?@B1+=[H#BNEKQ]2ZMTW0TZ1-2FT53
MP2.UQ%*/.1'5UN]+W*,I.#_R>>UM>#QSH14C)"V5/,%M:F9F$`05<2<5`4&'
M,;ZP")@7`GZ7CKK_`,3=:UY*K+8'BUN*TO$_"AI,NO-%Y;]WYRDZ,:'\4>,M
MN]:1@XBFJ;72JS#T@EMQ^M=[!D)\L<L[S\29R!7%"*H6+^,T%()F`\I+,<:1
M*;1)4.H"E1F9')]\:+%+X=1&@*%'S$!T15\:[N9-L4]"RK>KPTE/\Y]1\PZY
M;8H]ISW2O#!L.UURO&L+BT?U;:Z]PJEAM:1;Z-0ZB[E/1T_>3LG<YN2#I%]S
MG[B-OL$>1$3$J6/GECGV+951;U#H-5;&I7Z^R2`/$13B#;F\-A#7+^&.K+VH
M*U9>W7&QL0T#+':#F[G1B&Y[=LXZI]X5RY<)F54W+APLH:6J*O[36H886H`2
M!6&/'>6>C-5##HV1>CA7L%=O'$RC:0L=#M&;YY`I!/)Y;M3N59K+!L*BJM9@
MDX"L+@H;?ZJS178/+61VOA%HNW]Y]A=4YTO+*T].",$@=4NV-?\`B%[S3FFU
MNE=-:KE1:=MJC@W;:=+:@-P%0\7JA,NE#B9_!&7NFX_H^.X=K7Z#3JS3(-DB
MF@TB:Q"1T(P;HHIE1233:QS=LD4B:9"E#P\@VU(]-2TU(V&J5M#;0V)2D`#S
M2^*-%;_J?4FJJ]=SU-7UEPN+BBI3M0\MY:B2225.*49DDGM,=O`-=B+'\4<Z
M0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"
M&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:
M0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI".!_9#]?2
M$4:S9_\`)[S_`!:_^U:M=S_L_D$2!P[_`'ZGM'QQ$VYK_P`?E/N*_KGU!^I/
MUBH]M.7W^R,>3\48`,F?QUS_`(X?US:BJL_6*[3'IYI+]4GR?BBV\/,?_2_9
MU:3Z1[3$M'YL=PI_\<3_`,>/^!KL,;NW\<6&^_J5=GXHRG\9?X['_P"-:?[8
M76;VC]8GM_%&F7&'^SN_1/Q&)<W!C_>Z/_=D_P!K+J>--?JT^3XX\->9'^VO
M?1_'&58OE].LV^<.R-*U;(Y+\OZ7^"&N44.V/+2$-(0TA#2$-(0TA#2$-(1_
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
